

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 December 2001 (06.12.2001)

PCT

(10) International Publication Number
WO 01/91736 A2

(51) International Patent Classification⁷: **A61K 31/00**

(21) International Application Number: **PCT/US01/14793**

(22) International Filing Date: **8 May 2001 (08.05.2001)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
60/208,259 **31 May 2000 (31.05.2000)** **US**

(71) Applicant (*for all designated States except US*):
WARNER-LAMBERT COMPANY [—/US]; 201
Tabor Road, Morris Plains, NJ 07950 (US).

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): **DOOLEY, David,**
James [US/US]; Pfizer Inc., PGRD, Ann Arbor Laborato-
ries, 2800 Plymouth Road, Ann Arbor, MI 48105 (US).

(74) Agents: **FEDERMAN, Evan, J.**; Warner-Lambert Com-
pany, 201 Tabor Road, Morris Plains, NJ 07950 et al. (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).


Published:

— *without international search report and to be republished
upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: **COMBINATIONS OF AN ENDOTHELIN RECEPTOR ANTAGONIST AND AN ANTIEPILEPTIC COMPOUND
HAVING PAIN ALLEVIATING PROPERTIES OR ANALGESIC**

(57) Abstract: The present invention is a novel combination effective for alleviating pain comprising a pain alleviating effective amount of an endothelin receptor antagonist or a pharmaceutically acceptable salt thereof and from 1 to 3 compounds independently selected from the group consisting of antiepileptic compounds having pain alleviating properties and analgesics, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising same. The administration of endothelin receptor antagonists in these novel combinations results in an improved reduction in the frequency and severity of pain. The incidence of unwanted side effects can be reduced by these novel combinations in comparison to using higher doses of a single agent treatment to achieve a similar therapeutic effect. The present invention is also directed to methods of using effective amounts of the novel combinations and pharmaceutical compositions thereof to treat pain in mammals, including a human.



WO 01/91736 A2

-1-

COMBINATIONS OF AN ENDOTHELIN RECEPTOR ANTAGONIST AND
AN ANTIEPILEPTIC COMPOUND HAVING PAIN ALLEVIATING
PROPERTIES OR ANALGESIC

5 The present invention is directed to novel combinations effective for
alleviating pain comprising a pain alleviating effective amount of an endothelin
receptor antagonist or a pharmaceutically acceptable salt thereof, and one or two
compounds selected from the group consisting of antiepileptic compounds having
pain alleviating properties and analgesics, and to methods of treating or alleviating
10 pain comprising administering effective amounts of said combinations to a
mammal, including a human, in need of said treatment. The invention also is
directed to pharmaceutical compositions comprising said combinations.

BACKGROUND OF THE INVENTION

A number of treatments involving the administration of single drugs are
currently recommended for pain relief. It is well-known that single administration
15 of opioid and nonopioid analgesics have been shown to display pain alleviating
properties. Some antiepileptic compounds, such as gabapentin and pregabalin,
have also demonstrated pain alleviating properties.

Neurokinin 1 (NK₁) receptor antagonists are being developed for the
treatment of a number of physiological disorders associated with an excess or
20 imbalance of tachykinins, and in particular of substance P, an important
neurotransmitter in the transmission of pain. The selective NK₁ receptor
antagonist, [2-(1*H*-indol-3-yl)-1-methyl-1-(1-phenyl-ethylcarbamoyl)-ethyl]-
carbamic acid benzofuran-2-ylmethyl ester, has been shown to block the
maintenance of streptozotocin-induced static allodynia in the rat (Field et al.,
25 *J. Pharmacol. Exp. Ther.* 1998;285:1226-1232).

Recently, the endothelin receptor antagonist ABT-627 was found to
attenuate pain in a rat model of diabetic neuropathy (Jarvis M.F. et al., *Eur. J.*
Pharmacol. 2000;388:29-35). The antihyperalgesic effects are maintained after

-2-

chronic administration. This effect probably results from a block of ET_A receptors activated by endogenous endothelin-1, leading to deficits in neurovascular blood flow and nerve conduction velocities. Recently, another endothelin receptor antagonist, BQ-123, was shown to alleviate pain in a mouse model of inflammation and hyperalgesia (Piovezan A.P. et al., *Brit. J. Pharmacol.* 2000;129:961-968).

More recently, studies have shown that both endothelin A receptors and endothelin B receptors are involved in signaling pain, namely acute or neuropathic pain and chronic inflammatory pain, respectively (Pomonis J.D. et al., *J. Neurosci.* 2001;21(3):999-1006).

Endothelin-1 (ET-1), a potent vasoconstrictor, is a 21 amino acid bicyclic peptide that was first isolated from cultured porcine aortic endothelial cells. Endothelin-1 is one of a family of structurally similar bicyclic peptides which include ET-2, ET-3, vasoactive intestinal contractor (VIC), and the sarafotoxins (SRTXs).

Specific endothelin receptor antagonists that can be used herein are disclosed in:

United States Patent No. 5,599,811 is incorporated by reference.

United States Patent No. 5,482,960 is incorporated by reference.

Further, the following US patents recite certain endothelin antagonists and are incorporated by reference herein.

United States Patent Number:

5,382,569;

5,773,414;

5,641,752;

5,260,276;

5,922,681;

5,691,373;

6,017,916;

5,610,177;

5,658,943;

-3-

	5,922,759;
	6,051,599;
	6,043,265;
	6,043,241;
5	6,040,309;
	6,017,951;
	5,998,468;
	6,030,991;
	6,030,970;
10	6,022,886;
	6,020,348;
	6,017,952;
	6,017,945;
	6,017,939;
15	6,013,655;
	6,008,224;
	6,004,965;
	5,986,103;
	5,985,886;
20	5,977,117;
	5,977,075;
	5,969,151;
	5,968,971;
	5,965,732;
25	5,962,682;
	5,962,490;
	5,958,968;
	5,958,905;
	5,948,754;
30	5,942,516;
	5,939,446;
	5,929,116;
	5,929,106;

-4-

	5,925,731;
	5,916,907;
	5,888,972;
	5,883,092;
5	5,883,090;
	5,883,075;
	5,866,568;
	5,861,401;
	5,856,509;
10	5,856,484;
	5,846,990;
	5,846,985;
	5,840,722;
	5,834,483;
15	5,834,469;
	5,827,869;
	5,821,256;
	5,817,693;
	5,817,683;
20	5,817,653;
	5,804,585;
	5,780,498;
	5,780,473;
	5,767,144;
25	5,760,038;
	5,739,333;
	5,736,564;
	5,731,434;
	5,731,321;
30	5,728,706;
	5,726,194;
	5,719,183;
	5,719,182;

-5-

	5,716,985;
	5,716,984;
	5,714,479;
	5,703,106;
5	5,700,807;
	5,693,637;
	5,691,315;
	5,686,481;
	5,686,478;
10	5,668,176;
	5,668,137;
	5,658,902;
	5,656,604;
	5,654,309;
15	5,641,793;
	5,639,860;
	5,631,222;
	5,622,971;
	5,616,684;
20	5,614,498;
	5,614,497;
	5,612,359;
	5,594,021;
	5,591,761;
25	5,589,478;
	5,587,505;
	5,576,439;
	5,571,821;
	5,565,485;
30	5,559,135;
	5,559,105;
	5,550,138;
	5,550,110;

-6-

5,538,991;
5,538,950;
5,514,696;
5,514,691;
5 5,496,928;
5,494,897;
5,492,917;
5,492,892;
5,470,833;
10 5,464,853;
5,463,107;
5,444,152;
5,430,022;
5,420,133;
15 5,420,123;
5,401,745;
5,391,566;
5,389,620;
5,380,921;
20 5,378,715;
5,374,638;
5,352,659;
5,334,598;
5,248,807;
25 5,240,910;
5,187,195; and
5,114,918.

Further, the following PCT patent applications recite certain endothelin antagonists and are incorporated herein by reference.

30 WO Publication Number:
00/09489;
00/01389;
99/63936;

-7-

	99/56761;
	99/49866;
	99/48530;
	99/45002;
5	99/44988;
	99/42453;
	99/37639;
	99/36408;
	99/29685;
10	99/27934;
	99/25701;
	99/23078;
	99/20623;
	99/12916;
15	99/11629;
	99/06397;
	99/05132;
	99/02519;
	98/58916;
20	98/57938;
	98/57933;
	98/49162;
	98/42709;
	98/42702;
25	98/41521;
	98/41515;
	98/33780;
	98/27091;
	98/27077;
30	98/27070;
	98/09953;
	98/08836;
	97/37987;

-8-

97/37986;
97/37985;
97/30046;
97/30045;
5 97/28158;
97/28154;
97/25321;
97/19077;
97/17340;
10 97/13758;
96/04905;
95/26360;
94/21255;
94/02474;
15 93/23404; and
93/08799.

Specific antiepileptic compounds having pain alleviating properties are incorporated by reference and are disclosed in:

United States Patent No. 4,024,175;
20 United States Patent No. 4,087,544;
United States Patent No. 4,960,931;
United States Patent No. 5,563,175; and
WO Publications No. WO 92/09560;
WO 93/23383;
25 WO 98/17627;
WO 99/31057;
WO 99/31074; and
WO 99/31075.

PCT/US 98/23991 is incorporated by reference.

30 The NK₁ receptor antagonists, such as capsaicin, heretofore used to treat pain or a disorder exhibiting a pain component can be used herein. Specific

-9-

NK₁ receptor antagonists that can be used herein are disclosed in United States Patent Nos. 3,862,114, 3,912,711, 4,472,305, 4,481,139, 4,680,283, 4,839,465, 5,102,667, 5,162,339, 5,164,372, 5,166,136, 5,232,929, 5,242,944, 5,300,648, 5,310,743, 5,338,845, 5,340,822, 5,378,803, 5,410,019, 5,411,971, 5,420,297, 5,422,354, 5,446,052, 5,451,586, 5,525,712, 5,527,811, 5,536,737, 5,541,195, 5,594,022, 5,561,113, 5,576,317, 5,604,247, 5,624,950, and 5,635,510; World Patent Application Nos. WO 90/05525, WO 91/09844, WO 91/12266, WO 92/06079, WO 92/12151, WO 92/15585, WO 92/20661, WO 92/20676, WO 92/21677, WO 92/22569, WO 93/00330, WO 93/00331, WO 93/01159, WO 93/01160, WO 93/01165, WO 93/01169, WO 93/01170, WO 93/06099, WO 93/10073, WO 93/14084, WO 93/19064, WO 93/21155, WO 94/04496, WO 94/08997, WO 94/29309, WO 95/11895, WO 95/14017, WO 97/19942, WO 97/24356, WO 97/38692, WO 98/02158, and WO 98/07694; European Patent Application Nos. 284942, 327009, 333174, 336230, 360390, 394989, 428434, 429366, 443132, 446706, 484719, 499313, 512901, 512902, 514273, 514275, 515240, 520555, 522808, 528495, 532456, and 591040.

United States Patent No. 5,800,385 and WO 96/19233 are related and recite irrigation solutions comprised of anti-pain/anti-inflammation agents selected from: (1) serotonin receptor antagonists; (2) serotonin receptor agonists; (3) histamine receptor antagonists; (4) bradykinin receptor antagonists; (5) kallikrein inhibitors; (6) tachykinin receptor antagonists, including neurokinin₁ and neurokinin₂ receptor subtype antagonists; (7) calcitonin gene-related peptide (CGRP) receptor antagonists; (8) interleukin receptor antagonists; (9) inhibitors of enzymes active in the synthetic pathway for arachadonic acid metabolites, including (a) phospholipase inhibitors, including PLA₂ isoform inhibitors and PLC_γ isoform inhibitors, (b) cyclooxygenase inhibitors, and (c) lipoxygenase inhibitors; (10) prostanoid receptor antagonists including eicosanoid EP-1 and EP-4 receptor subtype antagonists and thromboxane receptor subtype antagonists; (11) leukotriene receptor antagonists including leukotriene B₄ receptor subtype antagonists and leukotriene D₄ receptor subtype antagonists;

-10-

(12) opioid receptor agonists, including mu-opiate, delta opiate, and kappa opiate receptor subtype agonists; (13) purinoceptor agonists and antagonists including P_{2X} receptor antagonists and P_{2Y} receptor agonists; (14) adenosine triphosphate (ATP)-sensitive potassium channel openers; and (15) calcium channel antagonists.

5 Further recited are irrigation solutions comprised of anti-pain/anti-inflammation agents as described above and an anti-spasm agent selected from anti-pain/anti-inflammation agents which also serve as an anti-spasm agent such as serotonin receptor antagonists, tachykinin receptor antagonists, ATP-sensitive potassium channel openers, and calcium channel antagonists and agents utilized specifically

10 for their anti-spasm properties such as endothelin receptor antagonists and the nitric oxide donors (enzyme activators).

WO 96/35453 recites methods of preventing/treating preterm labor, imminent abortion, dysmenorrhea, menstrual disorders (i.e., dysfunctional uterine bleeding, menorrhagia, breakthrough bleeding), preeclampsia of pregnancy which

15 utilize an endothelin antagonist and/or an endothelin synthase (ECE) inhibitor which may be used in combination with a progestational agent (progestin), a cyclooxygenase inhibitor and/or a nitric oxide (NO) donor and/or NO substrate. Further recited are methods of preventing/treating atherosclerotic vascular disease and hypertension with a combination of an endothelin antagonist and/or

20 endothelin synthase inhibitor with steroid hormones, and/or with an NO donor and/or NO substrate, and optionally with a cyclooxygenase inhibitor.

Despite the benefits derived from current single drug pain relief regimens, these regimens have disadvantages. One area of concern relates to the incidence of unwanted side effects caused by many of the pain treatment regimens available

25 today. Opioid analgesics, such as morphine, are sparingly prescribed for pain because of the well-known addictive effects and significant central nervous system (CNS) side effects and gastrointestinal side effects. Among nonopioid drugs often used alone for treatment of pain, nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen and naproxen, are criticized for their irritation of the

30 gastrointestinal tract.

-11-

Another concern of current pain treatment regimens relates to their effectiveness. Many single active ingredients employed in current pain relief regimens cannot achieve adequate pain alleviation even at their maximum therapeutic approved doses in some severe pain states. In addition to not achieving
5 adequate pain alleviation, increasing the drug dose may produce an increase in unwanted side effects such as cognitive impairment, nausea, and constipation.

In view of these concerns, it is evident that there is a need for an improved pain regimen that provides an improved therapeutic benefit (i.e., reduced severity and/or frequency of pain) and/or reduces the incidence of unwanted side effects
10 caused by many of the current regimens.

A combination of pain alleviating compounds including an endothelin receptor antagonist with one, two, or three known compounds selected from the group consisting of antiepileptic compounds having pain alleviating properties and analgesics would provide benefits to patients in need of pain alleviating
15 treatment not provided by administration of a higher dose of any single compound to achieve similar therapeutic benefit or by a combination of two or more pain alleviating compounds that did not include an endothelin receptor antagonist.

The inventors have now surprisingly found that endothelin receptor antagonists, when co-administered with compounds selected from the group consisting of antiepileptics having pain alleviating properties or analgesics, result
20 in unexpected improved pain relief. This finding is unexpected as the combination of an endothelin antagonist, which modulates diseases with a vascular component, and a pain alleviating agent to treat pain is not a combination that would have been obvious to one skilled in the medical arts at the time the invention was made.


All that is required to practice the present invention is to administer a therapeutically effective amount of the invention combination from 1 to 6 times
25 daily to a patient in need of treatment for alleviation of pain. As discussed below, determination of dosage forms, amounts of the invention combinations, and routes of administration, selection of compounds for inclusion in the invention combination, and identification of patients in need of treatment is within the level
30 of ordinary skill in the medical and pharmaceutical arts.

-12-

SUMMARY OF THE INVENTION

The present invention is combinations for alleviating pain. The combinations comprise a pain alleviating effective amount of an endothelin receptor antagonist or a pharmaceutically acceptable salt thereof and from 1 to 3 compounds independently selected from the group consisting of antiepileptic compounds having pain alleviating properties and analgesics, and pharmaceutically acceptable salts thereof. Nonlimiting examples of antiepileptic compounds having pain alleviating properties are gabapentin and pregabalin. Analgesics are selected from opioid analgesics and nonopioid analgesics. Nonlimiting examples of nonopioid analgesics include NSAIDs, N-methyl-D-aspartate (NMDA) receptor antagonists, and neurokinin 1 (NK₁) receptor antagonists.

In a preferred embodiment of the present invention, antiepileptics having pain alleviating properties include those that have the following Formula I:



I


wherein R₁ is hydrogen or a lower alkyl; n is an integer of from 4 to 6; and the cyclic ring is optionally substituted by lower alkyl or lower cycloalkyl, and the pharmaceutically acceptable salts thereof. The term lower alkyl includes straight or branched chain alkyl groups of up to eight carbon atoms. An especially preferred embodiment utilizes a compound of Formula I where R₁ is hydrogen and n is 5, which compound is 1-(aminomethyl)-cyclohexane acetic acid, known generically as gabapentin.

Other preferred compounds of Formula I above include, but are not limited to, ethyl 1-aminomethyl-1-cyclohexane-acetate, 1-aminomethyl-1-cycloheptane-acetic acid, 1-aminomethyl-1-cyclopentane-acetic acid, methyl-1-aminomethyl-1-cyclohexane-acetate, n-butyl 1-aminomethyl-1-cyclohexane-acetate, methyl 1-aminomethyl-1-cycloheptane-acetate, n-butyl 1-aminomethyl-1-cycloheptane-acetate, toluene sulfonate, 1-aminomethyl-1-cyclopentane-acetate, benzene-sulfonate, and n-butyl 1-aminomethyl-1-cyclopentane-acetate.

-13-

Other preferred compounds of Formula I above, wherein the cyclic ring is substituted for example with alkyl such as methyl or ethyl, include, but are not limited to (1-aminomethyl-3-methylcyclohexyl)acetic acid, (1-aminomethyl-3-methylcyclopentyl)acetic acid, and (1-aminomethyl-3,4-dimethylcyclopentyl)-acetic acid.


In another preferred embodiment of the present invention, antiepileptics having pain alleviating properties include those that are included in Formula II:




wherein R₁₁ is a straight or branched alkyl of from 1 to 6 carbon atoms, phenyl, or cycloalkyl having from 3 to 6 carbon atoms; R₁₂ is hydrogen or methyl; and R₁₃ is hydrogen, methyl, or carboxyl; or an individual diastereomeric or enantiomeric isomer thereof; or a pharmaceutically acceptable salt thereof.

The most preferred compound of Formula II is where R₁₂ and R₁₃ are both hydrogen, and R₁₁ is -(CH₂)₀₋₂-iC₄H₉ as an (R), (S), or (R,S) isomer. A more preferred embodiment of the invention utilizes 3-aminomethyl-5-methylhexanoic acid, and especially (S)-3-(aminomethyl)-5-methylhexanoic acid, now known generically as pregabalin. Pregabalin is also known as "CI-1008" and "S-(+)-IBG." Another preferred compound is 3-(1-aminoethyl)-5-methylhexanoic acid.

20 Another preferred embodiment of the present invention includes an antiepileptic compound having pain alleviating properties of Formula



-14-



or a pharmaceutically acceptable salt thereof wherein:

n is an integer of from 0 to 2;

m is an integer of from 0 to 3;

R is sulfonamide,

amide,


phosphonic acid,

heterocycle,

sulfonic acid, or


hydroxamic acid;

A' is a bridged ring selected from



-15-

wherein

 is the point of attachment;

Z₁ to Z₄ are each independently selected from hydrogen and methyl;

o is an integer of from 1 to 4; and

5 p is an integer of from 0 to 2.

In formula (1) above, R cannot be sulfonic acid when m is 2 and n is 1 (Suman-Chaulan N. et al., *European Journal of Pharmacology*, 1993;244:293-301).

Another preferred embodiment of the present invention includes a
10 compound of Formula III, IIIC, IIIF, IIIG, or IIIH selected from:

(1-Aminomethyl-cyclohexylmethyl)-phosphonic acid;
(1R-trans)(1-Aminomethyl-3-methyl-cyclohexylmethyl)-phosphonic acid;
(trans)(1-Aminomethyl-3,4-dimethyl-cyclopentylmethyl)-phosphonic acid;
(1R-trans)(1-Aminomethyl-3-methyl-cyclopentylmethyl)-phosphonic acid;
15 (1S-cis)(1-Aminomethyl-3-methyl-cyclopentylmethyl)-phosphonic acid;
(1S-trans)(1-Aminomethyl-3-methyl-cyclopentylmethyl)-phosphonic acid;
(1R-cis)(1-Aminomethyl-3-methyl-cyclopentylmethyl)-phosphonic acid;
(1 α ,3 α ,4 α)(1-Aminomethyl-3,4-dimethyl-cyclopentylmethyl)-phosphonic

acid;

20 (1 α ,3 β ,4 β)(1-Aminomethyl-3,4-dimethyl-cyclopentylmethyl)-phosphonic
acid;

(R)(1-Aminomethyl-3,3-dimethyl-cyclopentylmethyl)-phosphonic acid;
(S)(1-Aminomethyl-3,3-dimethyl-cyclopentylmethyl)-phosphonic acid;
(1-Aminomethyl-3,3-dimethyl-cyclobutylmethyl)-phosphonic acid;

25 2-(1-Aminomethyl-cyclohexyl)-N-hydroxy-acetamide;
(1S-trans)2-(1-Aminomethyl-3-methyl-cyclohexyl)-N-hydroxy-acetamide;
(trans)2-(1-Aminomethyl-3,4-dimethyl-cyclopentyl)-N-hydroxy-
acetamide;

(1S-cis)2-(1-Aminomethyl-3-methyl-cyclopentyl)-N-hydroxy-acetamide;
30 (1R-trans)2-(1-Aminomethyl-3-methyl-cyclopentyl)-N-hydroxy-
acetamide;

-16-

(1R-cis)2-(1-Aminomethyl-3-methyl-cyclopentyl)-N-hydroxy-acetamide;

(1S-trans)2-(1-Aminomethyl-3-methyl-cyclopentyl)-N-hydroxy-acetamide;

(1 α ,3 α ,4 α)2-(1-Aminomethyl-3,4-dimethyl-cyclopentyl)-N-hydroxy-acetamide;

(1 α ,3 β ,4 β)2-(1-Aminomethyl-3,4-dimethyl-cyclopentyl)-N-hydroxy-acetamide;

(S)2-(1-Aminomethyl-3,3-dimethyl-cyclopentyl)-N-hydroxy-acetamide;

(R)2-(1-Aminomethyl-3,3-dimethyl-cyclopentyl)-N-hydroxy-acetamide;

2-(1-Aminomethyl-3,3-dimethyl-cyclobutyl)-N-hydroxy-acetamide;

N-[2-(1-Aminomethyl-cyclohexyl)-ethyl]-methanesulfonamide;

(1S-cis)N-[2-(1-Aminomethyl-3-methyl-cyclohexyl)-ethyl]-methanesulfonamide;

(trans)N-[2-(1-Aminomethyl-3,4-dimethyl-cyclopentyl)-ethyl]-methanesulfonamide;

(1S-cis)N-[2-(1-Aminomethyl-3-methyl-cyclopentyl)-ethyl]-methanesulfonamide;

(1R-trans)N-[2-(1-Aminomethyl-3-methyl-cyclopentyl)-ethyl]-methanesulfonamide;

(1R-cis)N-[2-(1-Aminomethyl-3-methyl-cyclopentyl)-ethyl]-methanesulfonamide;

(1S-cis)N-[2-(1-Aminomethyl-3-methyl-cyclopentyl)-ethyl]-methanesulfonamide;

(1 α ,3 α ,4 α)N-[2-(1-Aminomethyl-3,4-dimethyl-cyclopentyl)-ethyl]-methanesulfonamide;

(1 α ,3 β ,4 β)N-[2-(1-Aminomethyl-3,4-dimethyl-cyclopentyl)-ethyl]-methanesulfonamide;

(S)N-[2-(1-Aminomethyl-3,3-dimethyl-cyclopentyl)-ethyl]-methanesulfonamide;

(R)N-[2-(1-Aminomethyl-3,3-dimethyl-cyclopentyl)-ethyl]-methanesulfonamide;

-17-

N-[2-(1-Aminomethyl-3,3-dimethyl-cyclobutyl)-ethyl]-
methanesulfonamide;

3-(1-Aminomethyl-cyclohexylmethyl)-4H-[1,2,4]oxadiazol-5-one;

3-(1-Aminomethyl-cyclohexylmethyl)-4H-[1,2,4]oxadiazol-5-one

5 hydrochloride;

(1S-cis)3-(1-Aminomethyl-3-methyl-cyclohexylmethyl)-4H-
[1,2,4]oxadiazol-5-one;

(trans)3-(1-Aminomethyl-3,4-dimethyl-cyclopentylmethyl)-4H-
[1,2,4]oxadiazol-5-one;

10 --- (1S-cis)3-(1-Aminomethyl-3-methyl-cyclopentylmethyl)-4H-
[1,2,4]oxadiazol-5-one;

(1R-trans)3-(1-Aminomethyl-3-methyl-cyclopentylmethyl)-4H-
[1,2,4]oxadiazol-5-one;

15 (1R-cis)3-(1-Aminomethyl-3-methyl-cyclopentylmethyl)-4H-
[1,2,4]oxadiazol-5-one;

(1S-trans)3-(1-Aminomethyl-3-methyl-cyclopentylmethyl)-4H-
[1,2,4]oxadiazol-5-one;

(1 α ,3 α ,4 α)3-(1-Aminomethyl-3,4-dimethyl-cyclopentylmethyl)-4H-
[1,2,4]oxadiazol-5-one;

20 (1 α ,3 β ,4 β)3-(1-Aminomethyl-3,4-dimethyl-cyclopentylmethyl)-4H-
[1,2,4]oxadiazol-5-one;

(S)3-(1-Aminomethyl-3,3-dimethyl-cyclopentylmethyl)-4H-
[1,2,4]oxadiazol-5-one;

25 (R)3-(1-Aminomethyl-3,3-dimethyl-cyclopentylmethyl)-4H-
[1,2,4]oxadiazol-5-one;

3-(1-Aminomethyl-3,3-dimethyl-cyclobutylmethyl)-4H-[1,2,4]oxadiazol-
5-one;

3-(1-Aminomethyl-cyclohexylmethyl)-4H-[1,2,4]oxadiazole-5-thione;

30 (1S-cis)3-(1-Aminomethyl-3-methyl-cyclohexylmethyl)-4H-
[1,2,4]oxadiazole-5-thione;

(trans)3-(1-Aminomethyl-3,4-dimethyl-cyclopentylmethyl)-4H-
[1,2,4]oxadiazole-5-thione;

-18-

(1S-cis)3-(1-Aminomethyl-3-methyl-cyclopentylmethyl)-4H-
[1,2,4]oxadiazole-5-thione;

(1R-trans)3-(1-Aminomethyl-3-methyl-cyclopentylmethyl)-4H-
[1,2,4]oxadiazole-5-thione;

5 (1R-cis)3-(1-Aminomethyl-3-methyl-cyclopentylmethyl)-4H-
[1,2,4]oxadiazole-5-thione;

(1S-trans)3-(1-Aminomethyl-3-methyl-cyclopentylmethyl)-4H-
[1,2,4]oxadiazole-5-thione;

10 (1 α ,3 α ,4 α)3-(1-Aminomethyl-3,4-dimethyl-cyclopentylmethyl)-4H-
[1,2,4]oxadiazole-5-thione;

(1 α ,3 β ,4 β)3-(1-Aminomethyl-3,4-dimethyl-cyclopentylmethyl)-4H-
[1,2,4]oxadiazole-5-thione;

(S)3-(1-Aminomethyl-3,3-dimethyl-cyclopentylmethyl)-4H-
[1,2,4]oxadiazole-5-thione;

15 (R)3-(1-Aminomethyl-3,3-dimethyl-cyclopentylmethyl)-4H-
[1,2,4]oxadiazole-5-thione;

3-(1-Aminomethyl-3,3-dimethyl-cyclobutylmethyl)-4H-[1,2,4]oxadiazole-
5-thione;

C-[1-(1H-Tetrazol-5-ylmethyl)-cyclohexyl]-methylamine;

20 (1S-cis)C-[3-Methyl-1-(1H-tetrazol-5-ylmethyl)-cyclohexyl]-
methylamine;

(trans)C-[3,4-Dimethyl-1-(1H-tetrazol-5-ylmethyl)-cyclopentyl]-
methylamine;

(1S-cis)C-[3-Methyl-1-(1H-tetrazol-5-ylmethyl)-cyclopentyl]-
25 methylamine;

(1R-trans)C-[3-Methyl-1-(1H-tetrazol-5-ylmethyl)-cyclopentyl]-
methylamine;

(1R-cis)C-[3-Methyl-1-(1H-tetrazol-5-ylmethyl)-cyclopentyl]-
methylamine;

30 (1S-trans)C-[3-Methyl-1-(1H-tetrazol-5-ylmethyl)-cyclopentyl]-
methylamine;

-19-

(1 α ,3 α ,4 α)C-[3,4-Dimethyl-1-(1H-tetrazol-5-ylmethyl)-cyclopentyl]-
methanamine;

(1 α ,3 β ,4 β)C-[3,4-Dimethyl-1-(1H-tetrazol-5-ylmethyl)-cyclopentyl]-
methanamine;

5 (S)C-[3,3-Dimethyl-1-(1H-tetrazol-5-ylmethyl)-cyclopentyl]-
methanamine;

(R)C-[3,3-Dimethyl-1-(1H-tetrazol-5-ylmethyl)-cyclopentyl]-
methanamine;

C-[3,3-Dimethyl-1-(1H-tetrazol-5-ylmethyl)-cyclobutyl]-methanamine;

10 N-[2-(1-Aminomethyl-cyclohexyl)-ethyl]-C,C,C-trifluoro-
methanesulfonamide;

(1S-cis)N-[2-(1-Aminomethyl-3-methyl-cyclohexyl)-ethyl]-C,C,C-
trifluoro-methanesulfonamide;

(trans)N-[2-(1-Aminomethyl-3,4-dimethyl-cyclopentyl)-ethyl]-C,C,C-
15 trifluoro-methanesulfonamide;

(1R-cis)N-[2-(1-Aminomethyl-3-methyl-cyclopentyl)-ethyl]-C,C,C-
trifluoro-methanesulfonamide;

(1S-trans)N-[2-(1-Aminomethyl-3-methyl-cyclopentyl)-ethyl]-C,C,C-
trifluoro-methanesulfonamide;

20 (1S-cis)N-[2-(1-Aminomethyl-3-methyl-cyclopentyl)-ethyl]-C,C,C-
trifluoro-methanesulfonamide;

(1R-trans)N-[2-(1-Aminomethyl-3-methyl-cyclopentyl)-ethyl]-C,C,C-
trifluoro-methanesulfonamide;

(1 α ,3 α ,4 α)N-[2-(1-Aminomethyl-3,4-dimethyl-cyclopentyl)-ethyl]-
25 C,C,C-trifluoro-methanesulfonamide;

(1 α ,3 β ,4 β)N-[2-(1-Aminomethyl-3,4-dimethyl-cyclopentyl)-ethyl]-C,C,C-
trifluoro-methanesulfonamide;

(S)N-[2-(1-Aminomethyl-3,3-dimethyl-cyclopentyl)-ethyl]-C,C,C-
trifluoro-methanesulfonamide;

30 (R)N-[2-(1-Aminomethyl-3,3-dimethyl-cyclopentyl)-ethyl]-C,C,C-
trifluoro-methanesulfonamide;

-20-

N-[2-(1-Aminomethyl-3,3-dimethyl-cyclobutyl)-ethyl]-C,C,C-trifluoromethanesulfonamide;

3-(1-Aminomethyl-cyclohexylmethyl)-4H-[1,2,4]thiadiazol-5-one;

(1S-cis)3-(1-Aminomethyl-3-methyl-cyclohexylmethyl)-4H-

5 [1,2,4]thiadiazol-5-one;

(trans)3-(1-Aminomethyl-3,4-dimethyl-cyclopentylmethyl)-4H-

[1,2,4]thiadiazol-5-one;

(1R-cis)3-(1-Aminomethyl-3-methyl-cyclopentylmethyl)-4H-

[1,2,4]thiadiazol-5-one;

10 (1S-trans)3-(1-Aminomethyl-3-methyl-cyclopentylmethyl)-4H-

[1,2,4]thiadiazol-5-one;

(1S-cis)3-(1-Aminomethyl-3-methyl-cyclopentylmethyl)-4H-

[1,2,4]thiadiazol-5-one;

(1R-trans)3-(1-Aminomethyl-3-methyl-cyclopentylmethyl)-4H-

15 [1,2,4]thiadiazol-5-one;

(1 α ,3 α ,4 α)3-(1-Aminomethyl-3,4-dimethyl-cyclopentylmethyl)-4H-

[1,2,4]thiadiazol-5-one;

(1 α ,3 β ,4 β)3-(1-Aminomethyl-3,4-dimethyl-cyclopentylmethyl)-4H-

[1,2,4]thiadiazol-5-one;

20 (S)3-(1-Aminomethyl-3,3-dimethyl-cyclopentylmethyl)-4H-

[1,2,4]thiadiazol-5-one;

(R)3-(1-Aminomethyl-3,3-dimethyl-cyclopentylmethyl)-4H-

[1,2,4]thiadiazol-5-one;

3-(1-Aminomethyl-3,3-dimethyl-cyclobutylmethyl)-4H-[1,2,4]thiadiazol-

25 5-one;

C-[1-(2-Oxo-2,3-dihydro-2 λ^4 -[1,2,3,5]oxathiadiazol-4-ylmethyl)-cyclohexyl]-methylamine;

(1S-cis)C-[3-Methyl-1-(2-oxo-2,3-dihydro-2 λ^4 -[1,2,3,5]oxathiadiazol-4-ylmethyl)-cyclohexyl]-methylamine;

30 (trans)C-[3,4-Dimethyl-1-(2-oxo-2,3-dihydro-2 λ^4 -[1,2,3,5]oxathiadiazol-4-ylmethyl)-cyclopentyl]-methylamine;

(1S-cis)C-[3-Methyl-1-(2-oxo-2,3-dihydro-2 λ ⁴-[1,2,3,5]oxathiadiazol-4-ylmethyl)-cyclopentyl]-methylamine;

(1R-trans)C-[3-Methyl-1-(2-oxo-2,3-dihydro-2 λ ⁴-[1,2,3,5]oxathiadiazol-4-ylmethyl)-cyclopentyl]-methylamine;

5 (1R-cis)C-[3-Methyl-1-(2-oxo-2,3-dihydro-2 λ ⁴-[1,2,3,5]oxathiadiazol-4-ylmethyl)-cyclopentyl]-methylamine;

(1S-trans)C-[3-Methyl-1-(2-oxo-2,3-dihydro-2 λ ⁴-[1,2,3,5]oxathiadiazol-4-ylmethyl)-cyclopentyl]-methylamine;

10 (1 α ,3 α ,4 α)C-[3,4-Dimethyl-1-(2-oxo-2,3-dihydro-2 λ ⁴-[1,2,3,5]oxathiadiazol-4-ylmethyl)-cyclopentyl]-methylamine;

(1 α ,3 β ,4 β)C-[3,4-Dimethyl-1-(2-oxo-2,3-dihydro-2 λ ⁴-[1,2,3,5]oxathiadiazol-4-ylmethyl)-cyclopentyl]-methylamine;

(S)C-[3,3-Dimethyl-1-(2-oxo-2,3-dihydro-2 λ ⁴-[1,2,3,5]oxathiadiazol-4-ylmethyl)-cyclopentyl]-methylamine;

15 (R)C-[3,3-Dimethyl-1-(2-oxo-2,3-dihydro-2 λ ⁴-[1,2,3,5]oxathiadiazol-4-ylmethyl)-cyclopentyl]-methylamine;

C-[3,3-Dimethyl-1-(2-oxo-2,3-dihydro-2 λ ⁴-[1,2,3,5]oxathiadiazol-4-ylmethyl)-cyclobutyl]-methylamine;

(1-Aminomethyl-cyclohexyl)-methanesulfonamide;

20 (1R-trans)(1-Aminomethyl-3-methyl-cyclohexyl)-methanesulfonamide;

(trans)(1-Aminomethyl-3,4-dimethyl-cyclopentyl)-methanesulfonamide;

(1S-trans)(1-Aminomethyl-3-methyl-cyclopentyl)-methanesulfonamide;

(1R-cis)(1-Aminomethyl-3-methyl-cyclopentyl)-methanesulfonamide;

(1R-trans)(1-Aminomethyl-3-methyl-cyclopentyl)-methanesulfonamide;

25 (1S-cis)(1-Aminomethyl-3-methyl-cyclopentyl)-methanesulfonamide;

(1 α ,3 β ,4 β)(1-Aminomethyl-3,4-dimethyl-cyclopentyl)-methanesulfonamide;

(1 α ,3 α ,4 α)(1-Aminomethyl-3,4-dimethyl-cyclopentyl)-methanesulfonamide;

30 (R)(1-Aminomethyl-3,3-dimethyl-cyclopentyl)-methanesulfonamide;

(S)(1-Aminomethyl-3,3-dimethyl-cyclopentyl)-methanesulfonamide;

-22-

- (1-Aminomethyl-3,3-dimethyl-cyclobutyl)-methanesulfonamide;
 (1-Aminomethyl-cyclohexyl)-methanesulfonic acid;
 (1R-trans) (1-Aminomethyl-3-methyl-cyclohexyl)-methanesulfonic acid;
 (trans)(1-Aminomethyl-3,4-dimethyl-cyclopentyl)-methanesulfonic acid;
 5 (1S-trans)(1-Aminomethyl-3-methyl-cyclopentyl)-methanesulfonic acid;
 (1S-cis)(1-Aminomethyl-3-methyl-cyclopentyl)-methanesulfonic acid;
 (1R-trans)(1-Aminomethyl-3-methyl-cyclopentyl)-methanesulfonic acid;
 (1R-cis)(1-Aminomethyl-3-methyl-cyclopentyl)-methanesulfonic acid;
 (1 α ,3 β ,4 β)(1-Aminomethyl-3,4-dimethyl-cyclopentyl)-methanesulfonic
 10 acid;
 (1 α ,3 α ,4 α)(1-Aminomethyl-3,4-dimethyl-cyclopentyl)-methanesulfonic
 acid;
 (R)(1-Aminomethyl-3,3-dimethyl-cyclopentyl)-methanesulfonic acid;
 (S)(1-Aminomethyl-3,3-dimethyl-cyclopentyl)-methanesulfonic acid;
 15 (1-Aminomethyl-3,3-dimethyl-cyclobutyl)-methanesulfonic acid;
 (1-Aminomethyl-cyclopentylmethyl)-phosphonic acid;
 2-(1-Aminomethyl-cyclopentyl)-N-hydroxy-acetamide;
 N-[2-(1-Aminomethyl-cyclopentyl)-ethyl]-methanesulfonamide;
 3-(1-Aminomethyl-cyclopentylmethyl)-4H-[1,2,4]oxadiazol-5-one;
 20 3-(1-Aminomethyl-cyclopentylmethyl)-4H-[1,2,4]oxadiazole-5-thione;
 C-[1-(1H-Tetrazol-5-ylmethyl)-cyclopentyl]-methylamine;
 N-[2-(1-Aminomethyl-cyclopentyl)-ethyl]-C,C,C-trifluoro-
 methanesulfonamide;
 3-(1-Aminomethyl-cyclopentylmethyl)-4H-[1,2,4]thiadiazol-5-one;
 25 C-[1-(2-Oxo-2,3-dihydro-2 λ ⁴-[1,2,3,5]oxathiadiazol-4-ylmethyl)-
 cyclopentyl]-methylamine;
 (1-Aminomethyl-cyclopentyl)-methanesulfonamide;
 (1-Aminomethyl-cyclopentyl)-methanesulfonic acid;
 (9-Aminomethyl-bicyclo[3.3.1]non-9-ylmethyl)-phosphonic acid;
 30 2-(9-Aminomethyl-bicyclo[3.3.1]non-9-yl)-N-hydroxy-acetamide;
 N-[2-(9-Aminomethyl-bicyclo[3.3.1]non-9-yl)-ethyl]-
 methanesulfonamide;

-23-

3-(9-Aminomethyl-bicyclo[3.3.1]non-9-ylmethyl)-4H-[1,2,4]oxadiazol-5-one;

3-(9-Aminomethyl-bicyclo[3.3.1]non-9-ylmethyl)-4H-[1,2,4]oxadiazole-5-thione;

5 C-[9-(1H-Tetrazol-5-ylmethyl)-bicyclo[3.3.1]non-9-yl]-methylamine;

N-[2-(9-Aminomethyl-bicyclo[3.3.1]non-9-yl)-ethyl]-C,C,C-trifluoromethanesulfonamide;

3-(9-Aminomethyl-bicyclo[3.3.1]non-9-ylmethyl)-4H-[1,2,4]thiadiazol-5-one;

10 C-[9-(2-Oxo-2,3-dihydro-2λ⁴-[1,2,3,5]oxathiadiazol-4-ylmethyl)-bicyclo[3.3.1]non-9-yl]-methylamine;

(9-Aminomethyl-bicyclo[3.3.1]non-9-yl)-methanesulfonamide;

(9-Aminomethyl-bicyclo[3.3.1]non-9-yl)-methanesulfonic acid;

(2-Aminomethyl-adamantan-2-ylmethyl)-phosphonic acid;

15 2-(2-Aminomethyl-adamantan-2-yl)-N-hydroxy-acetamide;

N-[2-(2-Aminomethyl-adamantan-2-yl)-ethyl]-methanesulfonamide;

3-(2-Aminomethyl-adamantan-2-ylmethyl)-4H-[1,2,4]oxadiazol-5-one;

3-(2-Aminomethyl-adamantan-2-ylmethyl)-4H-[1,2,4]oxadiazole-5-thione;

C-[2-(1H-Tetrazol-5-ylmethyl)-adamantan-2-yl]-methylamine;

20 N-[2-(2-Aminomethyl-adamantan-2-yl)-ethyl]-C,C,C-trifluoromethanesulfonamide;

3-(2-Aminomethyl-adamantan-2-ylmethyl)-4H-[1,2,4]thiadiazol-5-one;

C-[2-(2-Oxo-2,3-dihydro-2λ⁴-[1,2,3,5]oxathiadiazol-4-ylmethyl)-adamantan-2-yl]-methylamine;

25 (2-Aminomethyl-adamantan-2-yl)-methanesulfonamide;

(2-Aminomethyl-adamantan-2-yl)-methanesulfonic acid;

(1-Aminomethyl-cycloheptylmethyl)-phosphonic acid;

2-(1-Aminomethyl-cycloheptyl)-N-hydroxy-acetamide;

N-[2-(1-Aminomethyl-cycloheptyl)-ethyl]-methanesulfonamide;

30 3-(1-Aminomethyl-cycloheptylmethyl)-4H-[1,2,4]oxadiazol-5-one;

3-(1-Aminomethyl-cycloheptylmethyl)-4H-[1,2,4]oxadiazole-5-thione;

C-[1-(1H-Tetrazol-5-ylmethyl)-cycloheptyl]-methylamine;

-24-

N-[2-(1-Aminomethyl-cycloheptyl)-ethyl]-C,C,C-trifluoro-methanesulfonamide;

C-[1-(2-Oxo-2,3-dihydro-2H-[1,2,3,5]oxathiadiazol-4-ylmethyl)-cycloheptyl]-methylamine;

5 (1-Aminomethyl-cycloheptyl)-methanesulfonamide; and
(1-Aminomethyl-cycloheptyl)-methanesulfonic acid.


Another preferred embodiment of the present invention includes a compound of Formula III, IIIC, IIIF, IIIG, or IIIH, wherein preferred compounds are those wherein R is a sulfonamide selected from $\text{-NHSO}_2\text{R}^{15}$ or $\text{-SO}_2\text{NHR}^{15}$ wherein R^{15} is straight or branched alkyl or trifluoromethyl.

Another preferred embodiment of the present invention includes a compound of Formula III, IIIC, IIIF, IIIG, or IIIH, wherein especially preferred is N-[2-(1-aminomethyl-cyclohexyl)-ethyl]-methanesulfonamide.

Another preferred embodiment of the present invention includes a compound of Formula III, IIIC, IIIF, IIIG, or IIIH, wherein other preferred compounds are those wherein R is a phosphonic acid, $\text{-PO}_3\text{H}_2$.

Another preferred embodiment of the present invention includes a compound of Formula III, IIIC, IIIF, IIIG, or IIIH, wherein especially preferred are (1-aminomethyl-cyclohexylmethyl)-phosphonic acid and (2-aminomethyl-4-methyl-pentyl)-phosphonic acid.

Another preferred embodiment of the present invention includes a compound of Formula III, IIIC, IIIF, IIIG, or IIIH, wherein other preferred compounds are those wherein R is a heterocycle selected from:




Another preferred embodiment of the present invention includes a compound of Formula III, IIIC, IIIF, IIIG, or IIIH, wherein especially preferred are C-[1-(1H-tetrazol-5-ylmethyl)cyclohexyl]-methylamine and 4-methyl-2-(1H-tetrazol-5-ylmethyl)-pentylamine.

An especially preferred embodiment of the present invention includes a compound of Formula III wherein:

-25-


m is an integer of from 0 to 2;

p is an integer of 2; and



Still more preferred is an embodiment of the present invention which includes a compound of Formula III named 3-(1-aminomethyl-cyclohexylmethyl)-4H-[1,2,4]oxadiazol-5-one, and pharmaceutically acceptable salts thereof. Still more preferred is 3-(1-aminomethyl-cyclohexylmethyl)-4H-[1,2,4]oxadiazol-5-one hydrochloride.

Another preferred embodiment of the present invention includes a compound of Formula IV



IV

or a pharmaceutically acceptable salt thereof wherein:

R¹ is hydrogen, straight or branched alkyl of from 1 to 6 carbon atoms or phenyl;

R² is straight or branched alkyl of from 1 to 8 carbon atoms,

straight or branched alkenyl of from 2 to 8 carbon atoms,

cycloalkyl of from 3 to 7 carbon atoms,

alkoxy of from 1 to 6 carbon atoms,

- alkylcycloalkyl,

- alkylalkoxy,

- alkyl OH,

- alkylphenyl,

- alkylphenoxy,

- phenyl or substituted phenyl; and

R¹ is straight or branched alkyl of from 1 to 6 carbon atoms or phenyl when R² is methyl.

-26-

Preferred is an embodiment including a compound of Formula IV wherein R^1 is hydrogen, and R^2 is alkyl.

Another preferred embodiment includes a compound of Formula IV wherein R^1 is methyl, and R^2 is alkyl.

5 Still another preferred embodiment includes a compound of Formula IV wherein R^1 is methyl, and R^2 is methyl or ethyl.

Especially preferred is an embodiment including a compound of Formula IV selected from:

10 3-Aminomethyl-5-methylheptanoic acid;
3-Aminomethyl-5-methyl-octanoic acid;
3-Aminomethyl-5-methyl-nonanoic acid;
3-Aminomethyl-5-methyl-decanoic acid;
3-Aminomethyl-5-methyl-undecanoic acid;
3-Aminomethyl-5-methyl-dodecanoic acid;
15 3-Aminomethyl-5-methyl-tridecanoic acid;
3-Aminomethyl-5-cyclopropyl-hexanoic acid;
3-Aminomethyl-5-cyclobutyl-hexanoic acid;
3-Aminomethyl-5-cyclopentyl-hexanoic acid;
3-Aminomethyl-5-cyclohexyl-hexanoic acid;
20 3-Aminomethyl-5-trifluoromethyl-hexanoic acid;
3-Aminomethyl-5-phenyl-hexanoic acid;
3-Aminomethyl-5-(2-chlorophenyl)-hexanoic acid;
3-Aminomethyl-5-(3-chlorophenyl)-hexanoic acid;
3-Aminomethyl-5-(4-chlorophenyl)-hexanoic acid;
25 3-Aminomethyl-5-(2-methoxyphenyl)-hexanoic acid;
3-Aminomethyl-5-(3-methoxyphenyl)-hexanoic acid;
3-Aminomethyl-5-(4-methoxyphenyl)-hexanoic acid; and
3-Aminomethyl-5-(phenylmethyl)-hexanoic acid.

Another especially preferred embodiment includes compounds selected
30 from:
(3R,4S)-3-Aminomethyl-4,5-dimethyl-hexanoic acid;
3-Aminomethyl-4,5-dimethyl-hexanoic acid;

-27-

(3R,4S)-3-Aminomethyl-4,5-dimethyl-hexanoic acid MP;
(3S,4S)-3-Aminomethyl-4,5-dimethyl-hexanoic acid;
(3R,4R)-3-Aminomethyl-4,5-dimethyl-hexanoic acid MP;
3-Aminomethyl-4-isopropyl-hexanoic acid;
5 3-Aminomethyl-4-isopropyl-heptanoic acid;
3-Aminomethyl-4-isopropyl-octanoic acid;
3-Aminomethyl-4-isopropyl-nonanoic acid;
3-Aminomethyl-4-isopropyl-decanoic acid; and
3-Aminomethyl-4-phenyl-5-methyl-hexanoic acid.

10 Another preferred embodiment includes compounds selected from:

(3S,5S)-3-Aminomethyl-5-methoxy-hexanoic acid;
(3S,5S)-3-Aminomethyl-5-ethoxy-hexanoic acid;
(3S,5S)-3-Aminomethyl-5-propoxy-hexanoic acid;
(3S,5S)-3-Aminomethyl-5-isopropoxy-hexanoic acid;
15 (3S,5S)-3-Aminomethyl-5-*tert*-butoxy-hexanoic acid;
(3S,5S)-3-Aminomethyl-5-fluoromethoxy-hexanoic acid;
(3S,5S)-3-Aminomethyl-5-(2-fluoro-ethoxy)-hexanoic acid;
(3S,5S)-3-Aminomethyl-5-(3,3,3-trifluoro-propoxy)-hexanoic acid;
(3S,5S)-3-Aminomethyl-5-phenoxy-hexanoic acid;
20 (3S,5S)-3-Aminomethyl-5-(4-chloro-phenoxy)-hexanoic acid;
(3S,5S)-3-Aminomethyl-5-(3-chloro-phenoxy)-hexanoic acid;
(3S,5S)-3-Aminomethyl-5-(2-chloro-phenoxy)-hexanoic acid;
(3S,5S)-3-Aminomethyl-5-(4-fluoro-phenoxy)-hexanoic acid;
(3S,5S)-3-Aminomethyl-5-(3-fluoro-phenoxy)-hexanoic acid;
25 (3S,5S)-3-Aminomethyl-5-(2-fluoro-phenoxy)-hexanoic acid;
(3S,5S)-3-Aminomethyl-5-(4-methoxy-phenoxy)-hexanoic acid;
(3S,5S)-3-Aminomethyl-5-(3-methoxy-phenoxy)-hexanoic acid;
(3S,5S)-3-Aminomethyl-5-(2-methoxy-phenoxy)-hexanoic acid;
(3S,5S)-3-Aminomethyl-5-(4-nitro-phenoxy)-hexanoic acid;
30 (3S,5S)-3-Aminomethyl-5-(3-nitro-phenoxy)-hexanoic acid;
(3S,5S)-3-Aminomethyl-5-(2-nitro-phenoxy)-hexanoic acid;
(3S,5S)-3-Aminomethyl-6-hydroxy-5-methyl-hexanoic acid;
(3S,5S)-3-Aminomethyl-6-methoxy-5-methyl-hexanoic acid;

-28-

- (3S,5S)-3-Aminomethyl-6-ethoxy-5-methyl-hexanoic acid;
(3S,5S)-3-Aminomethyl-5-methyl-6-propoxy-hexanoic acid;
(3S,5S)-3-Aminomethyl-6-isopropoxy-5-methyl-hexanoic acid;
(3S,5S)-3-Aminomethyl-6-*tert*-butoxy-5-methyl-hexanoic acid;
5 (3S,5S)-3-Aminomethyl-6-fluoromethoxy-5-methyl-hexanoic acid;
(3S,5S)-3-Aminomethyl-6-(2-fluoro-ethoxy)-5-methyl-hexanoic acid;
(3S,5S)-3-Aminomethyl-5-methyl-6-(3,3,3-trifluoro-propoxy)-hexanoic
acid;
(3S,5S)-3-Aminomethyl-5-methyl-6-phenoxy-hexanoic acid;
10 (3S,5S)-3-Aminomethyl-6-(4-chloro-phenoxy)-5-methyl-hexanoic acid;
(3S,5S)-3-Aminomethyl-6-(3-chloro-phenoxy)-5-methyl-hexanoic acid;
(3S,5S)-3-Aminomethyl-6-(2-chloro-phenoxy)-5-methyl-hexanoic acid;
(3S,5S)-3-Aminomethyl-6-(4-fluoro-phenoxy)-5-methyl-hexanoic acid;
(3S,5S)-3-Aminomethyl-6-(3-fluoro-phenoxy)-5-methyl-hexanoic acid;
15 (3S,5S)-3-Aminomethyl-6-(2-fluoro-phenoxy)-5-methyl-hexanoic acid;
(3S,5S)-3-Aminomethyl-6-(4-methoxy-phenoxy)-5-methyl-hexanoic acid;
(3S,5S)-3-Aminomethyl-6-(3-methoxy-phenoxy)-5-methyl-hexanoic acid;
(3S,5S)-3-Aminomethyl-6-(2-methoxy-phenoxy)-5-methyl-hexanoic acid;
(3S,5S)-3-Aminomethyl-5-methyl-6-(4-trifluoromethyl-phenoxy)-hexanoic
20 acid;
(3S,5S)-3-Aminomethyl-5-methyl-6-(3-trifluoromethyl-phenoxy)-hexanoic
acid;
(3S,5S)-3-Aminomethyl-5-methyl-6-(2-trifluoromethyl-phenoxy)-hexanoic
acid;
25 (3S,5S)-3-Aminomethyl-5-methyl-6-(4-nitro-phenoxy)-hexanoic acid;
(3S,5S)-3-Aminomethyl-5-methyl-6-(3-nitro-phenoxy)-hexanoic acid;
(3S,5S)-3-Aminomethyl-5-methyl-6-(2-nitro-phenoxy)-hexanoic acid;
(3S,5S)-3-Aminomethyl-6-benzyloxy-5-methyl-hexanoic acid;
(3S,5S)-3-Aminomethyl-7-hydroxy-5-methyl-heptanoic acid;
30 (3S,5S)-3-Aminomethyl-7-methoxy-5-methyl-heptanoic acid;
(3S,5S)-3-Aminomethyl-7-ethoxy-5-methyl-heptanoic acid;
(3S,5S)-3-Aminomethyl-5-methyl-7-propoxy-heptanoic acid;
(3S,5S)-3-Aminomethyl-7-isopropoxy-5-methyl-heptanoic acid;

-29-

- (3S,5S)-3-Aminomethyl-7-*tert*-butoxy-5-methyl-heptanoic acid;
(3S,5S)-3-Aminomethyl-7-fluoromethoxy-5-methyl-heptanoic acid;
(3S,5S)-3-Aminomethyl-7-(2-fluoro-ethoxy)-5-methyl-heptanoic acid;
(3S,5S)-3-Aminomethyl-5-methyl-7-(3,3,3-trifluoro-propoxy)-heptanoic
5 acid;
(3S,5S)-3-Aminomethyl-7-benzyloxy-5-methyl-heptanoic acid;
(3S,5S)-3-Aminomethyl-5-methyl-7-phenoxy-heptanoic acid;
(3S,5S)-3-Aminomethyl-7-(4-chloro-phenoxy)-5-methyl-heptanoic acid;
(3S,5S)-3-Aminomethyl-7-(3-chloro-phenoxy)-5-methyl-heptanoic acid;
10 (3S,5S)-3-Aminomethyl-7-(2-chloro-phenoxy)-5-methyl-heptanoic acid;
(3S,5S)-3-Aminomethyl-7-(4-fluoro-phenoxy)-5-methyl-heptanoic acid;
(3S,5S)-3-Aminomethyl-7-(3-fluoro-phenoxy)-5-methyl-heptanoic acid;
(3S,5S)-3-Aminomethyl-7-(2-fluoro-phenoxy)-5-methyl-heptanoic acid;
(3S,5S)-3-Aminomethyl-7-(4-methoxy-phenoxy)-5-methyl-heptanoic acid;
15 (3S,5S)-3-Aminomethyl-7-(3-methoxy-phenoxy)-5-methyl-heptanoic
acid;
(3S,5S)-3-Aminomethyl-7-(2-methoxy-phenoxy)-5-methyl-heptanoic
acid;
(3S,5S)-3-Aminomethyl-5-methyl-7-(4-trifluoromethyl-phenoxy)-
20 heptanoic acid;
(3S,5S)-3-Aminomethyl-5-methyl-7-(3-trifluoromethyl-phenoxy)-
heptanoic acid;
(3S,5S)-3-Aminomethyl-5-methyl-7-(2-trifluoromethyl-phenoxy)-
heptanoic acid;
25 (3S,5S)-3-Aminomethyl-5-methyl-7-(4-nitro-phenoxy)-heptanoic acid;
(3S,5S)-3-Aminomethyl-5-methyl-7-(3-nitro-phenoxy)-heptanoic acid;
(3S,5S)-3-Aminomethyl-5-methyl-7-(2-nitro-phenoxy)-heptanoic acid;
(3S,5S)-3-Aminomethyl-5-methyl-6-phenyl-hexanoic acid;
(3S,5S)-3-Aminomethyl-6-(4-chloro-phenyl)-5-methyl-hexanoic acid;
30 (3S,5S)-3-Aminomethyl-6-(3-chloro-phenyl)-5-methyl-hexanoic acid;
(3S,5S)-3-Aminomethyl-6-(2-chloro-phenyl)-5-methyl-hexanoic acid;
(3S,5S)-3-Aminomethyl-6-(4-methoxy-phenyl)-5-methyl-hexanoic acid;
(3S,5S)-3-Aminomethyl-6-(3-methoxy-phenyl)-5-methyl-hexanoic acid;

-30-

- (3S,5S)-3-Aminomethyl-6-(2-methoxy-phenyl)-5-methyl-hexanoic acid;
(3S,5S)-3-Aminomethyl-6-(4-fluoro-phenyl)-5-methyl-hexanoic acid;
(3S,5S)-3-Aminomethyl-6-(3-fluoro-phenyl)-5-methyl-hexanoic acid;
(3S,5S)-3-Aminomethyl-6-(2-fluoro-phenyl)-5-methyl-hexanoic acid;
5 (3S,5R)-3-Aminomethyl-5-methyl-7-phenyl-heptanoic acid;
(3S,5R)-3-Aminomethyl-7-(4-chloro-phenyl)-5-methyl-heptanoic acid;
(3S,5R)-3-Aminomethyl-7-(3-chloro-phenyl)-5-methyl-heptanoic acid;
(3S,5R)-3-Aminomethyl-7-(2-chloro-phenyl)-5-methyl-heptanoic acid;
(3S,5R)-3-Aminomethyl-7-(4-methoxy-phenyl)-5-methyl-heptanoic acid;
10 (3S,5R)-3-Aminomethyl-7-(3-methoxy-phenyl)-5-methyl-heptanoic acid;
(3S,5R)-3-Aminomethyl-7-(2-methoxy-phenyl)-5-methyl-heptanoic acid;
(3S,5R)-3-Aminomethyl-7-(4-fluoro-phenyl)-5-methyl-heptanoic acid;
(3S,5R)-3-Aminomethyl-7-(3-fluoro-phenyl)-5-methyl-heptanoic acid;
(3S,5R)-3-Aminomethyl-7-(2-fluoro-phenyl)-5-methyl-heptanoic acid;
15 (3S,5R)-3-Aminomethyl-5-methyl-oct-7-enoic acid;
(3S,5R)-3-Aminomethyl-5-methyl-non-8-enoic acid;
(E)-(3S,5S)-3-Aminomethyl-5-methyl-oct-6-enoic acid;
(Z)-(3S,5S)-3-Aminomethyl-5-methyl-oct-6-enoic acid;
(Z)-(3S,5S)-3-Aminomethyl-5-methyl-non-6-enoic acid;
20 (E)-(3S,5S)-3-Aminomethyl-5-methyl-non-6-enoic acid;
(E)-(3S,5R)-3-Aminomethyl-5-methyl-non-7-enoic acid;
(Z)-(3S,5R)-3-Aminomethyl-5-methyl-non-7-enoic acid;
(Z)-(3S,5R)-3-Aminomethyl-5-methyl-dec-7-enoic acid;
(E)-(3S,5R)-3-Aminomethyl-5-methyl-undec-7-enoic acid;
25 (3S,5S)-3-Aminomethyl-5,6,6-trimethyl-heptanoic acid;
(3S,5S)-3-Aminomethyl-5,6-dimethyl-heptanoic acid;
(3S,5S)-3-Aminomethyl-5-cyclopropyl-hexanoic acid;
(3S,5S)-3-Aminomethyl-5-cyclobutyl-hexanoic acid;
(3S,5S)-3-Aminomethyl-5-cyclopentyl-hexanoic acid; and
30 (3S,5S)-3-Aminomethyl-5-cyclohexyl-hexanoic acid.

Still another more preferred embodiment includes a compound of
Formula IV selected from:

(3S,5R)-3-Aminomethyl-5-methyl-heptanoic acid;

-31-


- (3S,5R)-3-Aminomethyl-5-methyl-octanoic acid;
(3S,5R)-3-Aminomethyl-5-methyl-nonanoic acid;
(3S,5R)-3-Aminomethyl-5-methyl-decanoic acid;
(3S,5R)-3-Aminomethyl-5-methyl-undecanoic acid;
5 (3S,5R)-3-Aminomethyl-5-methyl-dodecanoic acid;
(3S,5R)-3-Aminomethyl-5,9-dimethyl-decanoic acid;
(3S,5R)-3-Aminomethyl-5,7-dimethyl-octanoic acid;
(3S,5R)-3-Aminomethyl-5,8-dimethyl-nonanoic acid;
(3S,5R)-3-Aminomethyl-6-cyclopropyl-5-methyl-hexanoic acid;
10 (3S,5R)-3-Aminomethyl-6-cyclobutyl-5-methyl-hexanoic acid;
(3S,5R)-3-Aminomethyl-6-cyclopentyl-5-methyl-hexanoic acid;
(3S,5R)-3-Aminomethyl-6-cyclohexyl-5-methyl-hexanoic acid;
(3S,5R)-3-Aminomethyl-7-cyclopropyl-5-methyl-heptanoic acid;
(3S,5R)-3-Aminomethyl-7-cyclobutyl-5-methyl-heptanoic acid;
15 (3S,5R)-3-Aminomethyl-7-cyclopentyl-5-methyl-heptanoic acid;
(3S,5R)-3-Aminomethyl-7-cyclohexyl-5-methyl-heptanoic acid;
(3S,5R)-3-Aminomethyl-8-cyclopropyl-5-methyl-octanoic acid;
(3S,5R)-3-Aminomethyl-8-cyclobutyl-5-methyl-octanoic acid;
(3S,5R)-3-Aminomethyl-8-cyclopentyl-5-methyl-octanoic acid;
20 (3S,5R)-3-Aminomethyl-8-cyclohexyl-5-methyl-octanoic acid;
(3S,5S)-3-Aminomethyl-6-fluoro-5-methyl-hexanoic acid;
(3S,5S)-3-Aminomethyl-7-fluoro-5-methyl-heptanoic acid;
(3S,5R)-3-Aminomethyl-8-fluoro-5-methyl-octanoic acid;
(3S,5R)-3-Aminomethyl-9-fluoro-5-methyl-nonanoic acid;
25 (3S,5S)-3-Aminomethyl-7,7,7-trifluoro-5-methyl-heptanoic acid;
(3S,5R)-3-Aminomethyl-8,8,8-trifluoro-5-methyl-octanoic acid;
(3S,5R)-3-Aminomethyl-5-methyl-8-phenyl-octanoic acid;
(3S,5S)-3-Aminomethyl-5-methyl-6-phenyl-hexanoic acid; and
(3S,5R)-3-Aminomethyl-5-methyl-7-phenyl-heptanoic acid.
30 Preferred is a combination of the invention comprising an endothelin antagonist that antagonizes both the ET_A and ET_B receptor subtypes.

-32-

Preferred is a combination of the invention comprising an endothelin antagonist that is selective for the ET_A receptor subtype.

Preferred is a combination of the invention comprising an endothelin antagonist that is selective for the ET_B receptor subtype.


5 Preferred is a combination of the invention comprising an endothelin antagonist which is a compound of Formula V



V

or a pharmaceutically acceptable acid addition or base salt thereof wherein:

R₂ is H,



alkyl of from 1 to 7 carbons, (CH₂)_n-cycloalkyl of from 3 to 8 carbons;

R_a and R_c are each 1 to 5 substituents and R_b is from 1 to 4 substituents

independently selected from:

hydrogen,

15

alkyl of from 1 to 7 carbons,

alkenyl of from 2 to 7 carbons,

alkynyl of from 2 to 7 carbons,

cycloalkyl of from 3 to 8 carbons,

phenyl,

20

C(O)-phenyl,

methylenedioxy,

ethylenedioxy,

OR,

NRR₁,

-33-

SR₁,NO₂,N₃,

COR,

5

CO₂R,

Cl,

Br,

F,

I,

10

CONRR₁,SO₂NRR₁,SO₂R,

CN,

CF₃,

15

CF₂CF₃,

CHO,

OCOR,

B(OH)₂,NH(CH₂)_pCO₂R,

20

S(CH₂)_pCO₂R,O(CH₂)_pCO₂R,O(CH₂)_pOR,NH(CH₂)_pOR,S(CH₂)_pOR, or

25

wherein R and R₁ are each independently selected from

hydrogen,

alkyl of from 1 to 6 carbon atoms,

alkenyl of from 2 to 7 carbon atoms,

alkynyl of from 2 to 7 carbon atoms,


30

cycloalkyl of from 3 to 8 carbon atoms,

-34-

phenyl or benzyl wherein the phenyl or benzyl ring is substituted by one or more hydrogen, methoxy, and methylenedioxy substituents;

R_d is H, CO_2R , SO_3R , PO_3R , $\text{B}(\text{OH})_2$, CONRR_1 , SO_2NRR_1 , $\text{C}(\text{O})\text{NHSO}_2\text{R}_1$,




n is an integer of from 0 to 2;

p is an integer of from 1 to 4;

--- indicates a single or double bond; and

X is $(\text{CH}_2)_n$, O, NR, or $\text{S}(\text{O})_n$.

10 Also preferred is a combination of the invention comprising an endothelin antagonist which is a compound of Formula VI



VI

wherein

--- denotes an optional bond;

15 n is 0 to 4;


R_a is hydrogen, alkyl of 1-4 carbon atoms or cycloalkyl, phenyl or naphthyl, in which the phenyl or naphthyl group is substituted by methylenedioxy and further unsubstituted or substituted by one or more substituents selected from the group consisting of halogen, alkyl of 1-6 carbon atoms, OR, NRR^1 , SR, NO_2 , N_3 , COR, CO_2R , CONRR^1 , SO_2NRR^1 , SO_2R , CN, CF_3 , CF_2CF_3 , CHO, OCOCH_3 , $\text{B}(\text{OH})_2$, phenyl, $\text{NH}(\text{CH}_2)_m\text{CO}_2\text{R}$, $\text{S}(\text{CH}_2)_m\text{CO}_2\text{R}$, $\text{O}(\text{CH}_2)_m\text{CO}_2\text{R}$, $\text{O}(\text{CH}_2)_m\text{OR}$, $\text{NH}(\text{CH}_2)_m\text{OR}$ and

20

-35-

$S(CH_2)_mOR$, in which m is 1, 2 or 3, and R and R^1 are each independently hydrogen, alkyl of 1-4 carbon atoms, phenyl or benzyl;

R_b is hydrogen, CO_2R^2 ,



5 SO_3R , PO_3H , $B(OH)_2$, $CONR^1R^2$, $SO_2NR^1R^2$, or



10 in which R^1 is as defined above and R^2 is hydrogen, alkyl of 1-6 carbon atoms, CF_3 , $-CF_2CF_3$, phenyl or benzyl in which phenyl or the phenyl portion of the benzyl group is unsubstituted or substituted by one or more substituents as defined above;

R_c is $S(O)_p$ -phenyl, in which p is 0, 1 or 2, and phenyl is unsubstituted or substituted by one or more substituents selected from the group consisting of halogen, OR, NRR^1 , SR, NO_2 , N_3 , COR, CO_2R , $CONRR^1$, SO_2NRR^1 , SO_2R , CN, CF_3 , CF_2CF_3 , CHO, $OCOCH_3$, $B(OH)_2$, methylenedioxy, $NH(CH_2)_mCO_2R$, $S(CH_2)_mCO_2R$, $O(CH_2)_mCO_2R$, $O(CH_2)_mOR$, $NH(CH_2)_mOR$ and $S(CH_2)_mOR$, in which m , R and R^1 are as defined above, and

20 R_d is 1 to 4 independent substituents selected from hydrogen, alkyl of 1-7 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, cycloalkyl, phenyl, $C(O)$ -phenyl, $X(CH_2)_n$ -phenyl, $X-(CH_2)_n$ -naphthyl, in which X is O, NH or $S(O)_p$, methylenedioxy, OR, NRR^1 , SR, NO_2 , N_3 , COR, CO_2R , $CONRR^1$, SO_2NRR^1 , SO_2R , CN, CF_3 , CF_2CF_3 , CHO, $OCOCH_3$, $B(OH)_2$, phenyl, $NH(CH_2)_mCO_2R$, $S(CH_2)_mCO_2R$, $O(CH_2)_mCO_2R$, $O(CH_2)_mOR$, $NH(CH_2)_mOR$, $S(CH_2)_mOR$, in which m is 1, 2 or 3 and R and R^1 are each independently hydrogen, alkyl of

25

-36-

1-4 carbon atoms, phenyl or benzyl and where n and p are as defined above and phenyl is unsubstituted or substituted as defined above, or a pharmaceutically acceptable acid addition or base salt thereof.

More preferred is a combination of the invention comprising an endothelin antagonist which is a compound selected from:

4-(3,5-Dimethyl-phenyl)-1, 1-dioxo-2-(2-trifluoromethyl-phenyl)-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid;

4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2*H*-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide;

4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2*H*-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide, potassium salt;

4-Benzo[1,3]dioxol-5-yl-2-methyl-1,1-dioxo-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid;

4-Benzo[1,3]dioxol-5-yl-2-benzo[1,3]dioxol-5-ylmethyl-1,1-dioxo-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid;

4-Benzo[1,3]dioxol-5-yl-2-benzyl-1,1-dioxo-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid;

4-Benzo[1,3]dioxol-5-yl-2-(4-methoxy-benzyl)-1,1-dioxo-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid;

4-Benzo[1,3]dioxol-5-yl-1,1-dioxo-2-(3,4,5-trimethoxy-benzyl)-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid;

4-Benzo[1,3]dioxol-5-yl-2-(2-carboxymethoxy-4-methoxy-benzyl)-1,1-dioxo-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid;

4-Benzo[1,3]dioxol-5-yl-2-(6-chloro-benzo[1,3]dioxol-5-ylmethyl)-1,1-dioxo-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid;

4-Benzo[1,3]dioxol-5-yl-2-(7-methoxy-benzo[1,3]dioxol-5-ylmethyl)-1,1-dioxo-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid;

2-Benzo[1,3]dioxol-5-ylmethyl-4-(3,4-dimethoxy-phenyl)-1,1-dioxo-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid;

2-Benzo[1,3]dioxol-5-ylmethyl-1,1-dioxo-4-(3,4,5-trimethoxy-phenyl)-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid;

-37-

N-(4-Benzo[1,3]dioxol-5-yl-2-benzo[1,3]dioxol-5-ylmethyl-1,1-dioxo-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carbonyl)-benzenesulfonamide;

2-Benzo[1,3]dioxol-5-ylmethyl-4-(3-methoxy-phenyl)-1,1-dioxo-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid;

5 4-Benzo[1,3]dioxol-5-yl-2-benzo[1,3]dioxol-5-ylmethyl-6,7-dimethoxy-1,1-dioxo-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid;

4-Benzo[1,3]dioxol-5-yl-2-benzo[1,3]dioxol-5-ylmethyl-6-methoxy-1,1-dioxo-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid;

10 8-Benzo[1,3]dioxol-5-yl-6-benzo[1,3]dioxol-5-ylmethyl-5,5-dioxo-5,6-dihydro-1,3-dioxo-5 λ ⁶-thia-6-aza-cyclopenta[b]naphthalene-7-carboxylic acid;

4-(Benzo[1,3]dioxol-5-ylsulfanyl)-2-methyl-1,1-dioxo-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid;

15 2-Benzo[1,3]dioxol-5-ylmethyl-4-(benzo[1,3]dioxol-5-ylsulfanyl)-1,1-dioxo-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid;

4-(Benzo[1,3]dioxol-5-ylsulfanyl)-2-benzyl-1,1-dioxo-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid;

4-(Benzo[1,3]dioxol-5-ylsulfanyl)-2-(4-methoxy-benzyl)-1,1-dioxo-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid;

20 4-(Benzo[1,3]dioxol-5-ylsulfanyl)-1,1-dioxo-2-(3,4,5-trimethoxy-benzyl)-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid;

4-(Benzo[1,3]dioxol-5-ylsulfanyl)-2-(carboxymethoxy-4-methoxy-benzyl)-1,1-dioxo-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid;

25 4-(Benzo[1,3]dioxol-5-ylsulfanyl)-2-(6-chloro-benzo[1,3]dioxol-5-ylmethyl)-1,1-dioxo-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid;

4-(Benzo[1,3]dioxol-5-ylsulfanyl)-2-(7-methoxy-benzo[1,3]dioxol-5-ylmethyl)-1,1-dioxo-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid;

2-Benzo[1,3]dioxol-5-ylmethyl-4-(3,4-dimethoxy-phenylsulfanyl)-1,1-dioxo-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid;

-38-

2-Benzo[1,3]dioxol-5-ylmethyl-1,1-dioxo-4-(3,4,5-trimethoxy-phenylsulfanyl)-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

N-(4-Benzo[1,3]dioxol-5-ylsulfanyl-2-benzo[1,3]dioxol-5-ylmethyl-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carbonyl)-benzenesulfonamide;

2-Benzo[1,3]dioxol-5-ylmethyl-4-(3-methoxy-phenylsulfanyl)-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

2-Benzo[1,3]dioxol-5-ylmethyl-4-(benzo[1,3]dioxol-5-ylsulfanyl)-6,7-dimethoxy-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

2-Benzo[1,3]dioxol-5-ylmethyl-4-(benzo[1,3]dioxol-5-ylsulfanyl)-6-methoxy-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

6-Benzo[1,3]dioxol-5-ylmethyl-8-(benzo[1,3]dioxol-5-ylsulfanyl)-5,5-dioxo-5,6-dihydro-1,3-dioxo-5 λ^6 -thia-6-aza-cyclopenta[b]naphthalene-7-carboxylic acid;

4-(Benzo[1,3]dioxol-5-ylsulfanyl)-2-isobutyl-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

2-Benzo[1,3]dioxol-5-ylmethyl-4-(benzo[1,3]dioxol-5-ylsulfanyl)-7-methoxy-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

2-Benzo[1,3]dioxol-5-ylmethyl-4-(2,3-dihydro-benzo[1,4]dioxin-6-ylsulfanyl)-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

4-(Benzo[1,3]dioxol-5-ylsulfanyl)-2-(2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

4-(Benzo[1,3]dioxol-5-ylsulfanyl)-2-cyclohexylmethyl-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

2-Benzo[1,3]dioxol-5-yl-4-(benzo[1,3]dioxol-5-ylsulfanyl)-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

2-Benzo[1,3]dioxol-5-yl-4-(benzo[1,3]dioxol-5-ylsulfanyl)-6,7-dimethoxy-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

2,4-Bis-benzo[1,3]dioxol-5-yl-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

2,4-Bis-benzo[1,3]dioxol-5-yl-6,7-dimethoxy-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

5 4-Benzo[1,3]dioxol-5-yl-2-(2-chloro-benzyl)-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

2-Benzo[1,3]dioxol-5-ylmethyl-4-(4-chloro-2,6-dimethoxy-phenyl)-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

10 4-(Benzo[1,3]dioxol-5-ylsulfanyl)-2-(2-chloro-benzyl)-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

2-Benzo[1,3]dioxol-5-ylmethyl-4-(4-chloro-2,6-dimethoxy-phenylsulfanyl)-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

15 4-(Benzo[1,3]dioxol-5-yl)-2-isobutyl-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

2-Benzo[1,3]dioxol-5-ylmethyl-4-(benzo[1,3]dioxol-5-yl)-7-methoxy-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

2-Benzo[1,3]dioxol-5-ylmethyl-4-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

20 4-(Benzo[1,3]dioxol-5-yl)-2-(2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

4-(Benzo[1,3]dioxol-5-yl)-2-cyclohexylmethyl-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

1-Benzo[1,3]dioxol-5-yl-3-phenylsulfanyl-1*H*-indole-2-carboxylic acid;

25 1-Benzo[1,3]dioxol-5-ylmethyl-5,6-dimethoxy-3-(3-methoxy-phenylsulfanyl)-1*H*-indole-2-carboxylic acid;

1-Benzo[1,3]dioxol-5-ylmethyl-3-(3-methoxy-phenylsulfanyl)-1*H*-indole-2-carboxylic acid;

1-Benzyl-3-(3-methoxy-phenylsulfanyl)-1*H*-indole-2-carboxylic acid;

30 1-Benzo[1,3]dioxol-5-ylmethyl-3-(benzo[1,3]dioxol-5-ylsulfanyl)-1*H*-indole-2-carboxylic acid;

-40-

5-Benzo[1,3]dioxol-5-ylmethyl-7-(3-methoxy-phenylsulfanyl)-5*H*-
[1,3]dioxolo[4,5-*f*]indole-6-carboxylic acid;

5-(7-Methoxy-benzo[1,3]dioxol-5-ylmethyl)-7-(3-methoxy-
phenylsulfanyl)-5*H*-[1,3]dioxolo[4,5-*f*]indole-6-carboxylic acid;

5 5-Benzo[1,3]dioxol-5-ylmethyl-7-(3,4-dimethoxy-phenylsulfanyl)-
5*H*-[1,3]dioxolo[4,5-*f*]indole-6-carboxylic acid;

7-(3,4-Dimethoxy-phenylsulfanyl)-5-(7-methoxy-benzo[1,3]dioxol-
5-ylmethyl)-5*H*-[1,3]dioxolo[4,5-*f*]indole-6-carboxylic acid;

10 1-Benzo[1,3]dioxol-5-ylmethyl-3-(3-methoxy-phenylsulfanyl)-6-propoxy-
1*H*-indole-2-carboxylic acid;

5,6-Dimethoxy-1-(7-methoxy-benzo[1,3]dioxol-5-ylmethyl)-
3-(3-methoxy-phenylsulfanyl)-1*H*-indole-2-carboxylic acid; and

5,6-Dimethoxy-1-(4-methoxy-benzyl)-3-(3-methoxy-phenylsulfanyl)-
1*H*-indole-2-carboxylic acid;

15 1-Benzo[1,3]dioxol-5-ylmethyl-5-benzyloxy-6-methoxy-3-(3-methoxy-
phenylsulfanyl)-1*H*-indole-2-carboxylic acid;

1-Benzo[1,3]dioxol-5-ylmethyl-5,6-dimethoxy-3-(3,4,5-trimethoxy-
phenylsulfanyl)-1*H*-indole-2-carboxylic acid;

20 1-Benzo[1,3]dioxol-5-ylmethyl-3-(benzo[1,3]dioxol-5-ylsulfanyl)-
6-benzyloxy-5-methoxy-1*H*-indole-2-carboxylic acid;

1-(2-Carboxymethoxy-4-methoxy-benzyl)-5,6-dimethoxy-3-(3-methoxy-
phenylsulfanyl)-1*H*-indole-2-carboxylic acid;

1-Benzo[1,3]dioxol-5-ylmethyl-3-(benzo[1,3]dioxol-5-ylsulfanyl)-
5,6-dimethoxy-1*H*-indole-2-carboxylic acid;

25 1-Benzo[1,3]dioxol-5-ylmethyl-3-(3,4,5-trimethoxy-phenylsulfanyl)-
6-benzyloxy-5-methoxy-1*H*-indole-2-carboxylic acid;

5-Benzo[1,3]dioxol-5-ylmethyl-7-(3,4,5-trimethoxy-phenylsulfanyl)-
5*H*-[1,3]dioxolo[4,5-*f*]indole-6-carboxylic acid; and

30 5-Benzo[1,3]dioxol-5-ylmethyl-7-(benzo[1,3]dioxol-5-ylsulfanyl)-
5*H*-[1,3]dioxolo[4,5-*f*]indole-6-carboxylic acid.

[2*S*-(2*Alpha*,3*Beta*,4*alpha*)]-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-
2-oxoethyl]-2-(4-methoxyphenyl)-3-pyrrolidinecarboxylic acid;

-41-

3-Pyrrolidinecarboxylic acid, 4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)-, sodium salt, (2R,3R,4S)-rel-;

N-[6-(2-Hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(1H-tetrazol-5-yl)-4-pyridinyl]-4-pyrimidinyl]-5-(1-methylethyl)-2-pyridinesulfonamide;

5 5-(Dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide;

4-(1,1-Dimethylethyl)-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]benzenesulfonamide;

10 Benzenesulfonamide, 4-(1,1-dimethyl)-N-[6-(2-hydroxyethoxy)-5-(3-methoxyphenoxy)-4-pyrimidinyl]-;

[N-cis-2,6-Dimethylpiperidinocarbonyl-L-.gamma.-methylleucyl-D-1-methoxycarbonyltryptophanyl-D-norleucine];

15 [5S-[5Alpha,6beta,7alpha(R*)]]-5-(1,3-benzodioxol-5-yl)-2-butyl-7-[2-(2-carboxypropyl)-4-methoxyphenyl]-6,7-dihydro-5H-cyclopenta[b]pyridine-6-carboxylic acid;

(5S-(5Alpha,6beta,7alpha(R*))) -2-butyl-5-(1,3-benzodioxol-5-yl)-7-((2-carboxypropyl)-4-methoxyphenyl)-6-dihydro-5H-cyclopenta(b)pyridine-6-carboxylic acid (J-104120);

20 (5S-(5Alpha,6beta,7alpha(R*))) -5-(1,3-benzodioxol-5-yl)-2-butyl-7-(2-(2-carboxypropyl)-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[b]pyridine-6-carboxylic acid (L-753037);

(S)-Alpha-[(4,6-Dimethoxy-2-pyrimidinyl)oxy]-beta-methoxy-beta-phenyl benzenepropanoic acid;

25 Alpha-((4,6-dimethoxy-2-pyrimidinyl)oxy)-beta-methoxy-beta-phenyl benzenepropanoic acid (LU-127043);

2-(4,6-Dimethoxypyrimidin-2-yloxy)-3-ethoxy-3,3-diphenylpropionic acid;

N-[6-(2-Hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(1H-tetrazol-5-yl)-4-pyridinyl]-4-pyrimidinyl]-5-methyl-2-pyridinesulfonamide;

30 2-Pyridinesulfonamide, N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(1H-tetrazol-5-yl)-4-pyridinyl]-4-pyrimidinyl]-5-methyl-;

-42-

27-O-3-[2-(3-Carboxy-acryloylamino)-5-hydroxyphenyl]-acryloyloxy
myricerone;

N-[6-[2-[(5-Bromo-2-pyrimidinyl)oxy]ethoxy]-5-(4-methylphenyl)-
4-pyrimidinyl]-4-(2-hydroxy-1,1-dimethylethyl)benzenesulfonamide
5 monosodium;

4-tert-Butyl-N-(5-(4-methylphenyl)-6-(2-(5-(3-thienyl)pyrimidin-
2-yloxy)ethoxy)pyrimidin-4-yl)-benzenesulfonamide (T-0115);

Cyclo[4-oxo-4-(4-phenyl-1-piperazinyl)-L-2-aminobutanoyl-L-alpha-
aspartyl-D-2-(2-thienyl)glycyl-L-leucyl-D-tryptophyl-D-alpha-aspartyl]disodium
10 salt;

N-(4-Chloro-3-methyl-5-isoxazolyl)-2-[(6-methyl-1,3-benzodioxol-
5-yl)acetyl]-3-thiophenesulfonamide;

2R-(4-Methoxyphenyl)-4S-(1,3-benzodioxol-5-yl)-1-(N,N-di(n-
butyl)aminocarbonyl-methyl)-pyrrolidine-3R-carboxylic acid (ABT-627);

3-Thiophenesulfonamide, N-(4-chloro-3-methyl-5-isoxazolyl)-
2-[(6-methyl-1,3-benzodioxol-5-yl)acetyl]- (IPI-1040);

3-Thiophenesulfonamide, N-(4-chloro-3-methyl-5-isoxazolyl)-
2-[(6-methyl-1,3-benzodioxol-5-yl)acetyl]- (IPI-1251); and

3-Thiophenesulfonamide, N-(4-chloro-3-methyl-5-isoxazolyl)-
2-[(6-methyl-1,3-benzodioxol-5-yl)acetyl]- (TBC-11241).
20

More preferred is a combination of the present invention wherein the
endothelin receptor antagonist is 4-(7-ethyl-1,3-benzodioxol-5-yl)-2-
[2-(trifluoromethyl)phenyl]-2H-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid,
1,1-dioxide, or a pharmaceutically acceptable salt thereof.


25 Still more preferred is a combination of the invention wherein the
endothelin receptor antagonist is 4-(7-ethyl-1,3-benzodioxol-5-yl)-2-
[2-(trifluoromethyl)phenyl]-2H-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid,
1,1-dioxide, potassium salt.

Also more preferred is a combination of the present invention wherein the
30 endothelin receptor antagonist is 4-(3,5-dimethyl-phenyl)-1,1-dioxo-2-(2-
trifluoromethyl-phenyl)-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid,
or a pharmaceutically acceptable salt thereof.

-43-

Still more preferred is a combination of the present invention wherein the endothelin receptor antagonist is 4-(3,5-dimethyl-phenyl)-1,1-dioxo-2-(2-trifluoromethyl-phenyl)-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid.

5 The compound named 4-(7-ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2H-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide, potassium salt is the compound of formula (1) shown below.



10 This compound is also known as 4-(7-ethyl-benzo[1,3]dioxol-5-yl)-1,1-dioxo-2-(2-trifluoromethyl-phenyl)-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid, potassium salt.

Also more preferred is a novel combination of the invention wherein the endothelin antagonist is selected from:

2R-(4-methoxyphenyl)-4S-(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonyl-methyl)-pyrrolidine-3R-carboxylic acid (ABT-627).

15 In a preferred embodiment of the present invention, the combination is comprised of compounds of Formula I, II, or III. In a more preferred embodiment of the present invention, the combination will contain the compound gabapentin, pregabalin, or 3-(1-aminomethyl-cyclohexylmethyl)-4H-[1,2,4]oxadiazol-5-one hydrochloride.

20 Also preferred is a novel combination of the invention wherein the antiepileptic compounds having pain alleviating properties is gabapentin and pregabalin.

More preferred is a novel combination of the invention wherein the endothelin receptor antagonist is selected from:

-44-

4-(3,5-Dimethyl-phenyl)-1,1-dioxo-2-(2-trifluoromethyl-phenyl)-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid;

4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2H-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide;

5 4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2H-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide, potassium salt; and

the antiepileptic compound having pain alleviating properties is selected from gabapentin, pregabalin, and 3-(1-aminomethyl-cyclohexylmethyl)-4H-[1,2,4]oxadiazol-5-one hydrochloride.

10 Also more preferred is a novel combination of the invention wherein the endothelin receptor antagonist is 4-(7-ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2H-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide, potassium salt, and the analgesic is an antiepileptic compound having pain alleviating properties named gabapentin.

15 Also more preferred is a novel combination of the invention wherein the endothelin receptor antagonist is 4-(7-ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2H-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide, potassium salt, and the analgesic is an antiepileptic compound having pain alleviating properties named pregabalin.

20 Also more preferred is a novel combination of the invention wherein the endothelin receptor antagonist is 4-(7-ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2H-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide, potassium salt, and the analgesic is an antiepileptic compound having pain alleviating properties named 3-(1-aminomethyl-cyclohexylmethyl)-4H-[1,2,4]oxadiazol-5-one hydrochloride.

25 Preferred is a novel combination of a pain alleviating effective amount of an endothelin receptor antagonist or a pharmaceutically acceptable salt thereof and from 1 to 3 compounds independently selected from the group consisting of antiepileptic compounds having pain alleviating properties and analgesics, and
30 pharmaceutically acceptable salts thereof, wherein the analgesic is an opioid analgesic.

-45-

More preferred is a novel combination of the invention wherein the analgesic is an opioid analgesic selected from:

Codeine;
Morphine;
5 Hydromorphone;
Levorphanol;
Methadone;
Oxycodone;
Hydrocodone;
10 Pentazocine;
Nalbuphine;
Butorphanol;
Hydromorphone; and
Naloxone.

15 Still more preferred is a novel combination of the invention wherein the endothelin receptor antagonist is selected from:

4-(3,5-Dimethyl-phenyl)-1,1-dioxo-2-(2-trifluoromethyl-phenyl)-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid;

4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2*H*-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide; and

20 4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2*H*-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide, potassium salt

and the analgesic is an opioid analgesic selected from:

Codeine;
25 Morphine;
Hydromorphone;
Levorphanol;
Methadone;
Oxycodone;
30 Hydrocodone;
Pentazocine;
Nalbuphine;

-46-

Butorphanol;
Hydromorphone; and
Naloxone.

5 Preferred is a novel combination of a pain alleviating effective amount of
an endothelin receptor antagonist or a pharmaceutically acceptable salt thereof and
from 1 to 3 compounds independently selected from the group consisting of
antiepileptic compounds having pain alleviating properties and analgesics, and
pharmaceutically acceptable salts thereof, wherein the analgesic is a nonopioid
analgesic.

10 Preferred is a novel combination of the invention wherein the analgesic is
an NSAID.

More preferred is a novel combination of the invention wherein the
analgesic is an NSAID selected from:

15 Naproxen;
Naproxen sodium;
Ibuprofen;
Acetaminophen;
Aspirin;
Sulindac;
20 Tolmetin;
Piroxicam;
Mefenamic acid;
Phenylbutazone;
Fenoprofen;
25 Ketoprofen;
Suprofen;
Diflunisal;
Celecoxib;
Meloxicam; and
30 (Z)-5-[[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]-
2-imino-4-thiazolidinone methanesulfonate (1:1).

Still more preferred is a novel combination of the invention wherein the
endothelin receptor antagonist is selected from:

-47-

4-(3,5-Dimethyl-phenyl)-1,1-dioxo-2-(2-trifluoromethyl-phenyl)-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid;

4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2H-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide; and

5 4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2H-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide, potassium salt

and the analgesic is an NSAID nonopioid analgesic selected from:

Naproxen;

Naproxen sodium;

10

Ibuprofen;

Acetaminophen;

Aspirin;

Sulindac;

Tolmetin;

15

Piroxicam;

Mefenamic acid;

Phenylbutazone;

Fenoprofen;

Ketoprofen;

20

Suprofen;

Diflunisal;

Celecoxib;

Meloxicam; and

(Z)-5-[[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]-

25

2-imino-4-thiazolidinone methanesulfonate (1:1).

Preferred is a novel combination of the invention wherein the analgesic is an NMDA receptor antagonist.

More preferred is a novel combination of the invention wherein the analgesic is an NMDA receptor antagonist selected from:

30

1H-Indole-2-carboxylic acid, 4,6-dichloro-3-[3-oxo-3-(phenylamino)-1-propenyl]-, (E)- (GV-150526);

-48-

1-Piperidineethanol, .alpha.-(4-hydroxyphenyl)-.beta.-methyl-
4-(phenylmethyl)- (Ifenprodil);

ACEA 1168; and

(1S,2S)-1-(4-Hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidine)-
5 1-propanol.

Still more preferred is a novel combination of the invention wherein the
endothelin receptor antagonist is selected from:

4-(3,5-Dimethyl-phenyl)-1,1-dioxo-2-(2-trifluoromethyl-phenyl)-
1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid;
10 4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2*H*-1,2-
dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide; and

4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2*H*-1,2-
dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide, potassium salt

and the analgesic is an NMDA receptor antagonist nonopioid analgesic
15 selected from:

1*H*-Indole-2-carboxylic acid, 4,6-dichloro-3-[3-oxo-3-(phenylamino)-
1-propenyl]-, (E)- (GV-150526);

1-Piperidineethanol, .alpha.-(4-hydroxyphenyl)-.beta.-methyl-
4-(phenylmethyl)- (Ifenprodil);

20 ACEA 1168; and

(1S,2S)-1-(4-Hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidine)-
1-propanol.

Preferred is a novel combination of the invention wherein the analgesic is
an NK₁ receptor antagonist.

25 More preferred is a novel combination of the invention wherein the
analgesic is an NK₁ receptor antagonist named:

[2-(1*H*-Indol-3-yl)-1-methyl-1-(1-phenyl-ethylcarbamoyl)-ethyl]-carbamic
acid benzofuran-2-ylmethyl ester.

30 Still more preferred is a novel combination of the invention wherein the
endothelin receptor antagonist is selected from:

4-(3,5-Dimethyl-phenyl)-1,1-dioxo-2-(2-trifluoromethyl-phenyl)-
1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid,

-49-

4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2*H*-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide, and

4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2*H*-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide, potassium salt;

5 and the analgesic is an NK₁ receptor antagonist nonopioid analgesic named:

[2-(1*H*-Indol-3-yl)-1-methyl-1-(1-phenyl-ethylcarbamoyl)-ethyl]-carbamic acid benzofuran-2-ylmethyl ester.

Preferred is a novel combination of a pain alleviating effective amount of an endothelin receptor antagonist or a pharmaceutically acceptable salt thereof and
10 from 1 to 3 compounds independently selected from the group consisting of antiepileptic compounds having pain alleviating properties and analgesics, and pharmaceutically acceptable salts thereof, wherein one compound is an antiepileptic compound having pain alleviating properties and one compound is an analgesic.

15 More preferred is a novel combination of the invention wherein one compound is an antiepileptic compound having pain alleviating properties and one compound is an opioid analgesic.

Still more preferred is a novel combination of the invention wherein the endothelin receptor antagonist is selected from:

20 4-(3,5-Dimethyl-phenyl)-1,1-dioxo-2-(2-trifluoromethyl-phenyl)-1,2-dihydro-1λ⁶-benzo[e][1,2]thiazine-3-carboxylic acid,

4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2*H*-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide, and

25 4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2*H*-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide, potassium salt;

the antiepileptic compound having pain alleviating properties is selected from gabapentin, pregabalin, and 3-(1-aminomethyl-cyclohexylmethyl)-4*H*-[1,2,4]oxadiazol-5-one hydrochloride; and

the analgesic is a nonopioid analgesic selected from:

30 Codeine;

Morphine;

Hydromorphone;

-50-

Levorphanol;
Methadone;
Oxycodone;
Hydrocodone;
5 Pentazocine;
Nalbuphine;
Butorphanol;
Hydromorphone; and
Naloxone.

10 More preferred is a novel combination of the invention wherein one compound is an antiepileptic compound having pain alleviating properties and one compound is a nonopioid analgesic.

Still more preferred is a novel combination of the invention wherein the endothelin receptor antagonist is selected from:

15 4-(3,5-Dimethyl-phenyl)-1,1-dioxo-2-(2-trifluoromethyl-phenyl)-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid;
4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2*H*-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide; and
4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2*H*-1,2-
20 dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide, potassium salt
the antiepileptic compound having pain alleviating properties is selected from gabapentin, pregabalin, and 3-(1-aminomethyl-cyclohexylmethyl)-4*H*-[1,2,4]oxadiazol-5-one hydrochloride; and

the analgesic is a nonopioid analgesic selected from:

25 Naproxen;
Naproxen sodium;
Ibuprofen;
Acetaminophen;
Aspirin;
30 Sulindac;
Tolmetin;
Piroxicam;

-51-

- Mefenamic acid;
 Phenylbutazone;
 Fenoprofen;
 Ketoprofen;
 5 Suprofen;
 Diflunisal;
 Celecoxib;
 Meloxicam;
 (Z)-5-[[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]-
 10 2-imino-4-thiazolidinone methanesulfonate (1:1);
 [2-(1*H*-Indol-3-yl)-1-methyl-1-(1-phenyl-ethylcarbamoyl)-ethyl]-
 carbamic acid benzofuran-2-ylmethyl ester;
 1*H*-Indole-2-carboxylic acid, 4,6-dichloro-3-[3-oxo-
 3-(phenylamino)-1-propenyl]-, (E)- (GV-150526);
 15 1-Piperidineethanol, .alpha.-(4-hydroxyphenyl)-.beta.-methyl-
 4-(phenylmethyl)- (Ifenprodil);
 ACEA 1168; and
 (1*S*,2*S*)-1-(4-Hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidine)-
 1-propanol.
 20 Preferred is a novel combination of a pain alleviating effective amount of
 an endothelin receptor antagonist or a pharmaceutically acceptable salt thereof and
 from 1 to 3 compounds independently selected from the group consisting of
 antiepileptic compounds having pain alleviating properties and analgesics, and
 pharmaceutically acceptable salts thereof, wherein one compound is an opioid
 25 analgesic and one compound is a nonopioid analgesic.
 Still more preferred is a novel combination of the invention wherein the
 endothelin receptor antagonist is selected from:
 4-(3,5-Dimethyl-phenyl)-1,1-dioxo-2-(2-trifluoromethyl-phenyl)-
 1,2-dihydro-1λ⁶-benzo[e][1,2]thiazine-3-carboxylic acid;
 30 4-(7-Ethyl-1,3-benzodiazol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2*H*-1,2-
 dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide; and

-52-

4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2H-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide, potassium salt

the opioid analgesic is selected from

Codeine;
Morphine;
Hydromorphone;
Levorphanol;
Methadone;
Oxycodone;
Hydrocodone;
Pentazocine;
Nalbuphine;
Butorphanol;
Hydromorphone; and
Naloxone;

and the nonopioid analgesic is selected from:

Naproxen;
Naproxen sodium;
Ibuprofen;
Acetaminophen;
Aspirin;
Sulindac;
Tolmetin;
Piroxicam;
Mefenamic acid;
Phenylbutazone;
Fenoprofen;
Ketoprofen;
Suprofen;
Diflunisal;
Celecoxib;
Meloxicam;

-53-

(Z)-5-[[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]-
2-imino-4-thiazolidinone methanesulfonate (1:1);

[2-(1*H*-Indol-3-yl)-1-methyl-1-(1-phenyl-ethylcarbamoyl)-ethyl]-
carbamic acid benzofuran-2-ylmethyl ester;

5 1*H*-Indole-2-carboxylic acid, 4,6-dichloro-3-[3-oxo-
3-(phenylamino)-1-propenyl]-, (E)- (GV-150526);

1-Piperidineethanol, .alpha.-(4-hydroxyphenyl)-.beta.-methyl-
4-(phenylmethyl)- (Ifenprodil);

ACEA 1168; and

10 (1*S*,2*S*)-1-(4-Hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidine)-
1-propanol.

Another embodiment of the present invention is a pharmaceutical
composition, comprising a pain alleviating effective amount of a combination of
an endothelin antagonist, or a pharmaceutically acceptable salt thereof, and from
15 1 to 3 compounds independently selected from the group consisting of
antiepileptic compounds having pain alleviating properties and analgesics, and
pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable
carrier, diluent, or excipient.

Another embodiment of the present invention is a method of treating pain
20 in a mammal suffering therefrom, comprising administering a pain alleviating
effective amount of a combination of an endothelin antagonist, or a
pharmaceutically acceptable salt thereof, and from 1 to 3 compounds
independently selected from the group consisting of antiepileptic compounds
having pain alleviating properties and analgesics, and pharmaceutically acceptable
25 salts thereof.

Preferred is a method of treating pain in a mammal suffering therefrom,
comprising administering a pain alleviating effective amount of a combination of
an endothelin antagonist, or a pharmaceutically acceptable salt thereof, and from
1 to 3 compounds independently selected from the group consisting of
30 antiepileptic compounds having pain alleviating properties and analgesics, and
pharmaceutically acceptable salts thereof, wherein the pain being treated is
selected from the group consisting of: centrally mediated pain, peripherally

-54-

mediated pain, structural pain, soft tissue pain, injury-related pain, progressive disease-related pain, and neuropathic pain.

Also preferred is a method of treating pain in a mammal suffering therefrom, comprising administering a pain alleviating effective amount of a combination of an endothelin antagonist, or a pharmaceutically acceptable salt thereof, and from 1 to 3 compounds independently selected from the group consisting of antiepileptic compounds having pain alleviating properties and analgesics, and pharmaceutically acceptable salts thereof, wherein the pain being treated is diabetic peripheral neuropathy.

Also preferred is a method of treating pain in a mammal suffering therefrom, comprising administering a pain alleviating effective amount of a combination of an endothelin antagonist, or a pharmaceutically acceptable salt thereof, and from 1 to 3 compounds independently selected from the group consisting of antiepileptic compounds having pain alleviating properties and analgesics, and pharmaceutically acceptable salts thereof, wherein the combination administered comprises an endothelin receptor antagonist which is 4-(7-ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2H-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide, potassium salt, and an antiepileptic compound having pain alleviating properties which is gabapentin, or a pharmaceutically acceptable salt thereof.

Also preferred is a method of treating pain in a mammal suffering therefrom, comprising administering a pain alleviating effective amount of a combination of an endothelin antagonist, or a pharmaceutically acceptable salt thereof, and from 1 to 3 compounds independently selected from the group consisting of antiepileptic compounds having pain alleviating properties and analgesics, and pharmaceutically acceptable salts thereof, wherein the combination administered comprises an endothelin receptor antagonist which is 4-(7-ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2H-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide, potassium salt, and an antiepileptic compound having pain alleviating properties which is pregabalin, or a pharmaceutically acceptable salt thereof.

Also preferred is a method of treating pain in a mammal suffering therefrom, comprising administering a pain alleviating effective amount of a

-55-

combination of an endothelin antagonist, or a pharmaceutically acceptable salt thereof, and from 1 to 3 compounds independently selected from the group consisting of antiepileptic compounds having pain alleviating properties and analgesics, and pharmaceutically acceptable salts thereof, wherein the
5 combination administered comprises an endothelin receptor antagonist which is 4-(7-ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2H-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide, potassium salt, and an antiepileptic compound having pain alleviating properties which is 3-(1-aminomethyl-cyclohexylmethyl)-4H-[1,2,4]oxadiazol-5-one hydrochloride, or a
10 pharmaceutically acceptable salt thereof.

Also preferred is a method of treating pain in a mammal suffering therefrom, comprising administering a pain alleviating effective amount of a combination of an endothelin antagonist, or a pharmaceutically acceptable salt thereof, and from 1 to 3 compounds independently selected from the group
15 consisting of antiepileptic compounds having pain alleviating properties and analgesics, and pharmaceutically acceptable salts thereof, wherein the pain being treated is diabetic peripheral neuropathy and the combination administered comprises an endothelin receptor antagonist which is 4-(7-ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2H-1,2-dihydro-1,2-benzothiazine-3-
20 carboxylic acid, 1,1-dioxide, potassium salt, and an antiepileptic compound having pain alleviating properties which is gabapentin, or a pharmaceutically acceptable salt thereof.

Also preferred is a method of treating pain in a mammal suffering therefrom, comprising administering a pain alleviating effective amount of a
25 combination of an endothelin antagonist, or a pharmaceutically acceptable salt thereof, and from 1 to 3 compounds independently selected from the group consisting of antiepileptic compounds having pain alleviating properties and analgesics, and pharmaceutically acceptable salts thereof, wherein the pain being treated is diabetic peripheral neuropathy and the combination administered
30 comprises an endothelin receptor antagonist which is 4-(7-ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2H-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide, potassium salt, and an antiepileptic compound

-56-

having pain alleviating properties which is pregabalin, or a pharmaceutically acceptable salt thereof.

Also preferred is a method of treating pain in a mammal suffering therefrom, comprising administering a pain alleviating effective amount of a combination of an endothelin antagonist, or a pharmaceutically acceptable salt thereof, and from 1 to 3 compounds independently selected from the group consisting of antiepileptic compounds having pain alleviating properties and analgesics, and pharmaceutically acceptable salts thereof, wherein the pain being treated is diabetic peripheral neuropathy and the combination administered comprises an endothelin receptor antagonist which is 4-(7-ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2H-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide, potassium salt, and an antiepileptic compound having pain alleviating properties which is 3-(1-aminomethyl-cyclohexylmethyl)-4H-[1,2,4]oxadiazol-5-one hydrochloride, or a pharmaceutically acceptable salt thereof.

Also preferred is a method of treating pain in a mammal suffering therefrom, comprising administering a pain alleviating effective amount of a combination of an endothelin antagonist, or a pharmaceutically acceptable salt thereof, and from 1 to 3 compounds independently selected from the group consisting of antiepileptic compounds having pain alleviating properties and analgesics, and pharmaceutically acceptable salts thereof, wherein the combination administered comprises an endothelin receptor antagonist which is 4-(3,5-dimethyl-phenyl)-1,1-dioxo-2-(2-trifluoromethylphenyl)-1,2-dihydro-1 λ 6-benzo[e][1,2]thiazine-3-carboxylic acid, and an antiepileptic compound having pain alleviating properties which is gabapentin, or a pharmaceutically acceptable salt thereof.

Also preferred is a method of treating pain in a mammal suffering therefrom, comprising administering a pain alleviating effective amount of a combination of an endothelin antagonist, or a pharmaceutically acceptable salt thereof, and from 1 to 3 compounds independently selected from the group consisting of antiepileptic compounds having pain alleviating properties and analgesics, and pharmaceutically acceptable salts thereof, wherein the

-57-

combination administered comprises an endothelin receptor antagonist which is 4-(3,5-dimethyl-phenyl)-1,1-dioxo-2-(2-trifluoromethylphenyl)-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid, and an antiepileptic compound having pain alleviating properties which is pregabalin, or a pharmaceutically acceptable salt thereof.

Also preferred is a method of treating pain in a mammal suffering therefrom, comprising administering a pain alleviating effective amount of a combination of an endothelin antagonist, or a pharmaceutically acceptable salt thereof, and from 1 to 3 compounds independently selected from the group consisting of antiepileptic compounds having pain alleviating properties and analgesics, and pharmaceutically acceptable salts thereof, wherein the combination administered comprises an endothelin receptor antagonist which is 4-(3,5-dimethyl-phenyl)-1,1-dioxo-2-(2-trifluoromethylphenyl)-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid, and an antiepileptic compound having pain alleviating properties which is 3-(1-aminomethyl-cyclohexylmethyl)-4H-[1,2,4]oxadiazol-5-one hydrochloride, or a pharmaceutically acceptable salt thereof.

Another embodiment of the present invention is a method of treating pain in a mammal suffering therefrom, comprising administering a pain alleviating effective amount of a pharmaceutical composition which comprises an endothelin antagonist, or a pharmaceutically acceptable salt thereof, and from 1 to 3 compounds independently selected from the group consisting of antiepileptic compounds having pain alleviating properties and analgesics, and pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier, diluent, or excipient.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 illustrates dose-response curves for gabapentin administered alone and the compound of formula (1) administered alone, expressed as the Pain Withdrawal Threshold (PWT) in grams of force of von Frey hairs measured at 1-hour postdose (the time point at which peak activity for each compound is

observed), versus oral dose of compound administered in milligrams of compound per kilogram of rat body weight. The compound of formula (1) is described below.

5 Figure 2 illustrates the dose-response curves for a combination of gabapentin and the compound of formula (1) administered at a 1:1 ratio (weight/weight), respectively, expressed as the PWT in grams of force of von Frey hairs versus total oral dose of the combination administered in total milligrams of the combination per kilogram of body weight, and the dose-response curves of Figure 1.

10 Figure 3 illustrates the dose-response curves for a combination of gabapentin and the compound of formula (1) administered at a 3:1 ratio (weight/weight), respectively, expressed as the PWT in grams of force of von Frey hairs versus total oral dose of the combination administered in total milligrams of the combination per kilogram of body weight, and the dose-response curves of Figure 1.

15 Figure 4 illustrates the dose-response curves for a combination of gabapentin and the compound of formula (1) administered at a 10:1 ratio (weight/weight), respectively, expressed as the PWT in grams of force of von Frey hairs versus total oral dose of the combination administered in total milligrams of the combination per kilogram of body weight, and the dose-response curves of Figure 1.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to novel combinations effective for alleviating pain comprising a pain alleviating effective amount of an endothelin
25 receptor antagonist or a pharmaceutically acceptable salt thereof, and one or two compounds selected from the group consisting of antiepileptic compounds having pain alleviating properties and analgesics, and to methods of treating or alleviating pain comprising administering effective amounts of said combinations to a mammal, including a human, in need of said treatment. The invention also is
30 directed to pharmaceutical compositions comprising said combinations.

-59-

In one embodiment of the present invention, a single endothelin receptor antagonist is combined with a single compound selected from the group consisting of antiepileptic compounds having pain alleviating properties, opioid analgesics, or nonopioid analgesics including NSAIDs, NMDA receptor antagonists, and NK₁ receptor antagonists. Preferred combinations include, but are not limited to, ET antagonist/opioid, ET antagonist/morphine, ET antagonist/hydrocodone, ET antagonist/oxycodone, ET antagonist/ibuprofen, ET antagonist/naproxen, ET antagonist/acetaminophen, ET antagonist/gabapentin, ET antagonist/pregabalin, and ET antagonist/3-(1-aminomethyl-cyclohexylmethyl)-4H-[1,2,4]oxadiazol-5-one hydrochloride.

In another embodiment of the present invention, a single endothelin antagonist is combined with two or three, preferably two, compounds selected from the group consisting of NSAIDs, opioid analgesics, NMDA receptor antagonists, NK₁ receptor antagonists, or combinations thereof. While any endothelin antagonist disclosed herein can be combined with any two or three compounds selected from NSAID, opioid analgesic, NMDA receptor antagonists, NK₁ receptor antagonists, or combinations thereof, the preferred ET receptor antagonists are:

4-(3,5-Dimethyl-phenyl)-1,1-dioxo-2-(2-trifluoromethyl-phenyl)-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid;

4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2H-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide; and

4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2H-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide, potassium salt.

Preferred combinations include, but are not limited to,

4-(3,5-Dimethyl-phenyl)-1,1-dioxo-2-(2-trifluoromethyl-phenyl)-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid/morphine/naproxen;

4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2H-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide/morphine/naproxen; and

4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2H-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide, potassium salt/morphine/naproxen.

-60-

Preferred combinations include, but are not limited to,

4-(3,5-Dimethyl-phenyl)-1,1-dioxo-2-(2-trifluoromethyl-phenyl)-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid/opioid/NSAID;

5 4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2*H*-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide/opioid/NSAID; and

4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2*H*-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide, potassium salt/opioid/NSAID.

Preferred combinations include, but are not limited to,

10 4-(3,5-Dimethyl-phenyl)-1,1-dioxo-2-(2-trifluoromethyl-phenyl)-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid/morphine/ibuprofen;

4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2*H*-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide/morphine/ibuprofen; and

15 4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2*H*-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide, potassium salt/morphine/ibuprofen.

Preferred combinations include, but are not limited to,

20 4-(3,5-Dimethyl-phenyl)-1,1-dioxo-2-(2-trifluoromethyl-phenyl)-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid/hydrocodone/acetaminophen;

4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2*H*-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide/hydrocodone/acetaminophen; and

25 4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2*H*-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide, potassium salt/hydrocodone/acetaminophen.

Preferred combinations include, but are not limited to,

30 4-(3,5-Dimethyl-phenyl)-1,1-dioxo-2-(2-trifluoromethyl-phenyl)-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid/oxycodone/acetaminophen;

-61-

4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2*H*-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide/oxycodone/acetaminophen; and

4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2*H*-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide, potassium salt/oxycodone/acetaminophen.

Preferred combinations include, but are not limited to,

4-(3,5-Dimethyl-phenyl)-1,1-dioxo-2-(2-trifluoromethyl-phenyl)-1,2-dihydro-1λ⁶-benzo[e][1,2]thiazine-3-carboxylic acid/gabapentin or pregabalin/morphine;

4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2*H*-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide/gabapentin; and pregabalin/morphine; and

4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2*H*-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide, potassium salt/gabapentin, or pregabalin/morphine.

Preferred combinations include, but are not limited to,

4-(3,5-Dimethyl-phenyl)-1,1-dioxo-2-(2-trifluoromethyl-phenyl)-1,2-dihydro-1λ⁶-benzo[e][1,2]thiazine-3-carboxylic acid/gabapentin or pregabalin/hydrocodone;

4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2*H*-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide/gabapentin or pregabalin/hydrocodone; and

4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2*H*-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide, potassium salt/gabapentin or pregabalin/hydrocodone.

Preferred combinations include, but are not limited to,

4-(3,5-Dimethyl-phenyl)-1,1-dioxo-2-(2-trifluoromethyl-phenyl)-1,2-dihydro-1λ⁶-benzo[e][1,2]thiazine-3-carboxylic acid/gabapentin or pregabalin/oxycodone;

-62-

4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2*H*-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide/gabapentin or pregabalin/oxycodone; and

5 4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2*H*-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide, potassium salt/gabapentin or pregabalin/oxycodone.

Preferred combinations include, but are not limited to,

4-(3,5-Dimethyl-phenyl)-1,1-dioxo-2-(2-trifluoromethyl-phenyl)-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid/gabapentin or
10 -- pregabalin/acetaminophen;

4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2*H*-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide/gabapentin or pregabalin/acetaminophen; and

15 4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2*H*-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide, potassium salt/gabapentin or pregabalin/acetaminophen.

Preferred combinations include, but are not limited to,

4-(3,5-Dimethyl-phenyl)-1,1-dioxo-2-(2-trifluoromethyl-phenyl)-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid/gabapentin or pregabalin/
20 ibuprofen;

4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2*H*-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide/gabapentin or pregabalin/ibuprofen; and

25 4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2*H*-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide, potassium salt/gabapentin or pregabalin/ibuprofen.

Preferred combinations include, but are not limited to,

4-(3,5-Dimethyl-phenyl)-1,1-dioxo-2-(2-trifluoromethyl-phenyl)-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid/gabapentin or pregabalin/
30 naproxen;

-63-

4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2*H*-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide/gabapentin or pregabalin/naproxen; and

5 4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2*H*-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide, potassium salt/gabapentin or pregabalin/naproxen.

In another embodiment of the present invention, two or more antiepileptic compounds having pain alleviating properties are combined with an endothelin receptor antagonist and optionally NSAIDs, NMDA receptor antagonists, or NK₁ receptor antagonists, or combinations thereof. While any antiepileptics
10 herein can be combined with any endothelin receptor antagonist and optionally with one or more compounds selected from NSAIDs, NMDA receptor antagonists, or NK₁ receptor antagonists, or combinations thereof, the preferred antiepileptic compounds having pain alleviating properties are chosen from the
15 compounds of Formulas I, II, and III, and the preferred ET antagonists are chosen from the compounds of Formulas V and VI. Preferred combinations include, but are not limited to, gabapentin/pregabalin/ET antagonist, gabapentin/pregabalin/ET antagonist/NSAID, gabapentin/pregabalin/naproxen/ET antagonist, and gabapentin/pregabalin/ET antagonist/opioid.

20 Any of the combinations disclosed herein can be used for treatment. The types of treatable pain experienced by mammals is varied and known to medical practitioners. Nonlimiting examples of mammalian pain include centrally mediated pain, peripherally mediated pain, structural or soft tissue injury related pain, progressive disease related pain (i.e., oncology) and neuropathic pain states,
25 all of which would include both acute (i.e., acute injury or trauma, pre- and postsurgical, headache such as a migraine), chronic (i.e., neuropathic pain conditions such diabetic peripheral neuropathy and posthepatic neuralgia), and inflammatory condition (i.e., osteo- or rheumatoid arthritis, sequela to acute injury or trauma) pain states.

30 Nonlimiting examples of mammalian pain being treated are centrally mediated pain, peripherally mediated pain, structural or soft tissue pain, injury-related pain, progressive disease-related pain, or neuropathic pain. Pain states

-64-

include both acute (e.g., acute injury or trauma, pre- and postsurgical, headache such as migraine), chronic (e.g., pain from cancer, neuropathic pain conditions such as diabetic peripheral neuropathy and posthepatic neuralgia), and inflammatory conditions (e.g., osteo- or rheumatoid arthritis, sequela to acute injury or trauma).

The term "mammal" includes a human, dog, cat, cow, sheep, pig, and horse.

As used herein, the phrase "effective amount" means the amount of a combination of the present invention that is effective for alleviating pain in a mammal suffering therefrom. The phrase "therapeutically effective amount," as used herein, means the same as the phrase "effective amount."

As used herein, the term "co-administration" is meant to include the administration of endothelin receptor antagonists before, during, or after administration of compounds selected from the group consisting of antiepileptics that demonstrate pain alleviating properties such as gabapentin and pregabalin, opioid analgesics, or nonopioid analgesics including NSAIDs, NMDA receptor antagonists, or NK₁ receptor antagonists.

One advantage of using the novel combinations described herein is the reduced severity and/or frequency of pain. Another potential advantage is the overall improvement in pain control, which can include a reduction in the dosage and unwanted side effects in comparison to using higher doses of a single agent treatment to achieve a similar therapeutic effect.

The present invention is valuable because combination approaches to pain alleviation take advantage of the unique properties and mechanisms of action of two or more different drugs. As discussed above, endothelin antagonists alleviate pain by a novel mechanism of action. An endothelin antagonist, an antiepileptic compound having pain alleviating properties, and an analgesic each independently contribute to pain alleviating activity by distinct mechanisms of action, so a combination of an endothelin antagonist with one or more drugs selected from the group consisting of antiepileptic compound having pain alleviating properties and analgesics will be more effective at the same doses than any single drug administered by itself (i.e., show a synergistic effect). Also, administration of

-65-

combinations may allow the use of smaller doses of each individual drug to achieve a certain level of pain alleviation comparable to higher doses of a single drug, and thereby reduce or avoid side effects connected with administration of higher doses.

5 The phrase "endothelin receptor antagonist" as used in this invention may be used interchangeably with the phrases endothelin antagonist or ET antagonist and are taken to mean the same. A preferred endothelin receptor antagonist is 4-(7-ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2*H*-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide, and
10 pharmaceutically acceptable salts thereof. A preferred pharmaceutically acceptable salt thereof is the potassium salt. Another preferred endothelin receptor antagonist is 4-(3,5-dimethyl-phenyl)-1,1-dioxo-2-(2-trifluoromethyl-phenyl)-1,2-dihydro-1 λ ⁶-benzo[e][1,2]-thiazine-3-carboxylic acid, and pharmaceutically acceptable salts thereof.

15 Analgesics used in this invention can be, for example, opioid analgesics or nonopioid analgesic compounds.

Nonopioid analgesics are generally defined to be those compounds that relieve pain without binding to opioid receptors. Nonlimiting examples of nonopioid analgesics include NSAIDs such as acetaminophen, NMDA receptor
20 antagonists, and NK₁ receptor antagonists. Nonopioid analgesics are typically nonaddictive.

Nonlimiting examples of clinically validated analgesics include the following:

25 Opiate mu receptor agonists;
Cyclooxygenase-2 (COX-2) inhibitors;
Sodium (Na⁺) channel blockers (e.g., PN3, SNS, brain type III, SCN10A, and SCN3A);
NR1/NR2B NMDA receptor antagonists;
Voltage-gated Calcium (Ca⁺²) channel antagonists (e.g., CACNA1B,
30 CACNA1A, and CACNA1E);
Alpha-2-adrenoceptor agonists; and
5-HT1A receptor antagonists.

-66-

Nonlimiting examples of preclinically validated analgesics include the following:

Tachykinin-1, -2, and -3 receptor antagonists;

Cannabinoid receptor antagonists;

5 MAP kinase enzyme cascade inhibitors (e.g., MEK inhibitors);

GluR5 KA receptor antagonists;

mGluR1 and mGluR5 receptor (Group I metabotropic glutamate receptors) antagonists;

Muscarinic M₄ and M₁ receptor antagonists;

10 Prostaglandin PGE₂ (P₁) receptor antagonists;

Opiate delta receptor agonists; and

Adenosine kinase inhibitors.

Opioid analgesics are generally defined to be those compounds that relieve pain and bind to opioid receptors. Opioid agonists and opioid agonist-antagonists are opioid analgesics and are addictive when administered to treat a mammal for pain. Opioid antagonists are nonaddictive. Nonlimiting examples of opioid analgesics include opiates, opiate derivatives, opioids, and their pharmaceutically acceptable salts. Specific nonlimiting examples of opioid agonist analgesics include alfentanil, alphaprodine, anileridine, bezitramide, codeine, 20 dihydrocodeine, diphenoxylate, ethylmorphine, fentanyl, heroin, hydrocodone, hydromorphone, isomethadone, levomethorphan, morphine, neperidine, oxycodone, phenomorphan, phenoperidine, piritradide, pholcodine, proheptazaine, properidine, propiran, racemoramide, thebacon, trimeperidine, and the pharmaceutically acceptable salts thereof. Specific nonlimiting examples of 25 opioid agonist-antagonist analgesics include pentazocine, butorphanol, nalbuphine, buprenorphine, and the pharmaceutically acceptable salts thereof. Specific nonlimiting examples of opioid antagonist analgesics include naloxone, naltrexone, and the pharmaceutically acceptable salts thereof.

The phrase "neurokinin 1 receptor antagonist" means nontoxic compounds that block or interfere with binding to the NK₁ receptor subtype. Preferred 30 NK₁ receptor antagonists that can be used herein are disclosed in United States Patent No. 5,594,022. Among these, a more preferred NK₁ receptor antagonist is

-67-

[2-(1*H*-indol-3-yl)-1-methyl-1-(1-phenyl-ethylcarbamoyl)-ethyl]-carbamic acid benzofuran-2-ylmethyl ester.

The expression "N-methyl-D-aspartate receptor" shall be understood to include all of the binding site subcategories associated with the NMDA receptor, e.g., the glycine-binding site, the phencyclidine (PCP)-binding site, etc., as well as the NMDA channel. The invention, herein contemplates the use of nontoxic substances that block or interfere with an NMDA receptor binding site. In one preferred embodiment NMDA receptor antagonists which can be used in the novel combinations are compounds that block or reduce the effects of NMDA at the NMDA subclass of neuronal glutamate receptors (nonlimiting examples include dextrorphan, dextromethorphan, and ketamine) or that block or interfere with the NMDA channel (e.g., a substance that blocks the magnesium or calcium channel). In another preferred embodiment, the NMDA receptor antagonist is one which is specific for a subtype of NMDA receptor, those containing the NR2B subunit which are expressed in the forebrain (nonlimiting examples include (1*S*,2*S*)-1-(4-hydroxyphenyl) 2-(4-hydroxy-4-phenylpiperidine)-1-propanol). Other NMDA receptor antagonists acting at other sites of an NMDA receptor include, but are not limited to 1*H*-indole-2-carboxylic acid, 4,6-dichloro-3-[3-oxo-3-(phenylamino)-1-propenyl]-, (E)- (GV-150526) (a compound in preclinical development by Glaxo Wellcome), 1-piperidineethanol, .alpha.-(4-hydroxyphenyl)-.beta.-methyl-4-(phenylmethyl)- (ifenprodil), and ACEA's 1168.

The term "NSAID," as used to describe other compounds useful in the novel combination herein, is intended to be a nonsteroidal anti-inflammatory compound. NSAIDs are categorized by virtue of their ability to inhibit cyclooxygenase. Cyclooxygenase 1 and cyclooxygenase 2 are the two major isoforms of cyclooxygenase and most standard NSAIDs are mixed inhibitors of the two isoforms. Most standard NSAIDs fall within one of the following five structural categories: (1) propionic acid derivatives, such as ibuprofen, naproxen, naprosyn, diclofenac, and ketoprofen; (2) acetic acid derivatives, such as tolmetin and sulindac; (3) fenamic acid derivatives, such as mefenamic acid and meclofenamic acid; (4) biphenylcarboxylic acid derivatives, such as diflunisal and flufenisal; and (5) oxicams, such as piroxim, peroxicam, sudoxicam, and isoxicam.

-68-

Other useful NSAIDs include aspirin, acetaminophen, indomethacin, and phenylbutazone.

Another class of NSAID has recently been described which selectively inhibits cyclooxygenase-2 (COX-2). These compounds reduce pain and inhibit the inflammatory response without damaging the gastric mucosa, a common toxicity observed with the mixed inhibitors.

(Z)-5-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]-2-imino-4-thiazolidinone methanesulfonate (1:1);

Celecoxib;

Meloxicam;

COX-189 (Novartis);

CS-502 (Sankyo);

Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro-(etodolac);

4-(4-Cyclohexyl-2-methyloxazol-5-yl)-2-fluorobenzenesulfonamide (JTE-522);

2-(3,5-Difluorophenyl)-3-(4-methylsulfonyl)phenyl)-2-cyclopenten-1-one (L-776967):

L-791456 (Merck & Co);

MK-663 (Merck & Co);

Methanesulfonamide;

N-(4-Nitro-2-phenoxyphenyl)- (nimesulide);

Propanamide;

N-((4-(5-Methyl-3-phenyl-4-isoxazolyl)phenyl)sulfonyl)- (parecoxib);

2(5H)-Furanone;

4-(4-(Methylsulfonyl)phenyl)-3-phenyl- (rofecoxib);

5(E)-(3,5-di-tert-Butyl-4-hydroxy)benzylidene-2-ethyl-1,2-isothiazolidine-1,1-dioxide (S-2474);

S-33516 (Servier);

Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)- (valdecoxib);

CT 3 (Channel);

GR 253035 (Glaxo Wellcome);

-69-

N-[6-[(2,4-Difluorophenyl)thio]-2,3-dihydro-1-oxo-1H-inden-5-yl]methanesulfonamide (L 745337);

L 748731 (Merck & Co);

L 752860 (Merck & Co);

5 (R)-1-[(4-bromophenyl)methyl]-5-methoxy-beta,2-dimethyl-1H-indole-3-butanoic acid (L 761066);

5-[4-(methylsulfonyl)phenyl]-6-phenylthiazolo[3,2-b][1,2,4]triazole (L 768277);

LAS 33826 (Almirall Prodesfama);

10 N-[5-[(4-fluorophenoxy)-2-thienyl]methanesulfonamide (RWJ 63556);
SD 8381 (Searle);

and their pharmaceutically acceptable salts are examples of selective cyclooxygenase 2 inhibitors.

15 The phrase "antiepileptic compound" means a pharmaceutically active compound that treats disorders characterized by recurring attacks of motor, sensory, or psychic malfunction with or without unconsciousness or convulsive movement.


20 The phrase "antiepileptic compound having pain alleviating properties" means an antiepileptic compound as defined above which also alleviates pain in a mammal, including a human. Many antiepileptic compound having pain alleviating properties are known such as, for example, the structural analogs of gamma-aminobutyric acid (GABA) or glutamic acid. Examples are gabapentin, pregabalin, and 3-(1-aminomethyl-cyclohexylmethyl)-4H-[1,2,4]oxadiazol-5-one hydrochloride. Gabapentin has been shown to possess pain alleviating properties
25 in animal models of inflammation and neuropathic pains, and in particular to block the maintenance of streptozotocin-induced static allodynia in the rat (Field et al., *J. Pharmacol. Exp. Ther.* 1997;282:1242-1246). Since determination of pain alleviating activity of an antiepileptic compound in an animal model of pain alleviation is well known in the pharmaceutical arts, it is a simple matter to
30 test any antiepileptic compound for pain alleviating properties. Nonlimiting examples of antiepileptics having pain alleviating properties include gabapentin, pregabalin, 3-(1-aminomethyl-cyclohexylmethyl)-4H-[1,2,4]oxadiazol-5-one

-70-

hydrochloride, carbamazepine, lamotrigine, phenytoin, fosphenytoin, and analogues thereof.

As noted above, the combinations of this invention may include any GABA analog. The preferred GABA analogs to be utilized in the method of this invention are cyclic amino acids of Formula I. These are described in United States Patent No. 4,024,175 and its divisional United States Patent No. 4,087,544, which are incorporated herein by reference. Another preferred method utilizes the GABA analogs of Formula II, and these are described in United States Patent No. 5,563,175, which is incorporated herein by reference. Another preferred method utilizes the GABA analogs of Formula III, IIIC, IIIF, IIIG, and IIIH, and these are described in PCT International Application WO 99/31075, which is herein incorporated by reference. Another preferred method utilizes the GABA analogs of Formula IV.

Other preferred GABA analogs are described in PCT International Application No. WO 99/31074. Such GABA analogs are novel compounds of formula (1A) and (1B)



or a pharmaceutically acceptable salt thereof wherein:

n is an integer of from 0 to 2;

R is sulfonamide,

amide,

phosphonic acid,


heterocycle,

sulfonic acid, or

hydroxamic acid;

A is hydrogen or methyl; and

-71-




straight or branched alkyl of from 1 to 11 carbons, or

$\text{---}(\text{CH}_2)_{1-4}\text{---Y---}(\text{CH}_2)_{0-4}\text{---phenyl}$ wherein Y is ---O--- , ---S--- , $\text{---NR}'_3$ wherein:

R'₃ is alkyl of from 1 to 6 carbons, cycloalkyl of from 3 to 8 carbons,

- 5 benzyl or phenyl wherein benzyl or phenyl can be unsubstituted or substituted with from 1 to 3 substituents each independently selected from alkyl, alkoxy, halogen, hydroxy, carboxy, carboalkoxy, trifluoromethyl, and nitro.

- 10 Other preferred GABA analogs are described in PCT International Application No. WO 99/31057. Such GABA analogs are novel compounds of formula (1D) and (1E)



or a pharmaceutically acceptable salt thereof wherein:

n is an integer of from 0 to 2;

- 15 R is sulfonamide,

amide,

phosphonic acid,

heterocycle,

sulfonic acid, or


- 20 hydroxamic acid; and

X is ---O--- , ---S--- , ---S(O)--- , $\text{---S(O)}_2\text{---}$, or NR'_1 wherein R'₁ is hydrogen, straight or branched alkyl of from 1 to 6 carbons, benzyl, $\text{---C(O)R}'_2$ wherein R'₂ is straight or branched alkyl of 1 to 6 carbons, benzyl or phenyl or $\text{---CO}_2\text{R}'_3$ wherein R'₃ is straight or branched alkyl of from 1 to 6 carbons, or benzyl

-72-

wherein the benzyl or phenyl groups can be unsubstituted or substituted by from 1 to 3 substituents selected from halogen, trifluoromethyl, and nitro.


Other preferred GABA analogs are described in PCT International Application No. WO 98/17627. Such GABA analogs are novel compounds of
 5 formula



or a pharmaceutically acceptable salt thereof wherein:

R is hydrogen or lower alkyl;

R₁ is hydrogen or lower alkyl;



straight or branched alkyl of from 7 to 11 carbon atoms, or

$\text{---}(\text{CH}_2)_{(1-4)}\text{---X---}(\text{CH}_2)_{(0-4)}\text{---phenyl}$ wherein

X is ---O--- , ---S--- , $\text{---NR}_3\text{---}$ wherein


R₃ is alkyl of from 1 to 6 carbons, cycloalkyl of from 3 to 8 carbons,

15 benzyl or phenyl;

wherein phenyl and benzyl can be unsubstituted or substituted with from 1 to 3 substituents each independently selected from alkyl, alkoxy, halogen, hydroxy, carboxy, carboalkoxy, trifluoromethyl, amino, and nitro.

20 Other preferred GABA analogs are described in PCT International Application No. WO 99/61424. Such GABA analogs are novel compounds of formulas (1), (2), (3), (4), (5), (6), (7), and (8)

-73-



or a pharmaceutically acceptable salt thereof or a prodrug thereof wherein:

5 R_1 to R_{10} are each independently selected from hydrogen or a straight or

branched alkyl of from 1 to 6 carbons, benzyl, or phenyl;

m is an integer of from 0 to 3;

n is an integer of from 1 to 2;

o is an integer of from 0 to 3;

10 p is an integer of from 1 to 2;

q is an integer of from 0 to 2;

r is an integer of from 1 to 2;

s is an integer of from 1 to 3;

t is an integer of from 0 to 2; and

15 u is an integer of from 0 to 1.

-74-

International patent applications WO 99/31074, WO 99/31057, WO 98/17627, and WO 99/61424 are herein incorporated by reference.

Antiepileptic compounds having pain alleviating properties such as gabapentin and pregabalin are alpha-2-delta (gabapentin receptor) antagonists.

5 The term "pain alleviating properties" is generally defined herein to include the expressions "pain-suppressing," "pain-reducing," and "pain-inhibiting" as the invention is applicable to the alleviation of existing pain, as well as the suppression or inhibition of pain which would otherwise ensue from an imminent pain-causing event.

10 In addition to its pain alleviating properties, gabapentin is extremely well-tolerated and has been demonstrated to be virtually free of drug interactions.

 In the compounds of Formulas I through IV, the term "alkyl" means a straight or branched hydrocarbon radical having from 1 to 12 carbon atoms unless otherwise specified and includes, for example, methyl, ethyl, n-propyl, isopropyl,
15 n-butyl, sec-butyl, isobutyl, tert-butyl, allyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, undecyl, and dodecyl.

 The phrase "lower alkyl" means a straight or branched chain alkyl group of from 1 to 8 carbon atoms unless otherwise specified and includes, for example, methyl ethyl, isobutyl, pentyl, 3,3-dimethylhexyl, and 2-ethylpentyl.

20 The term "alkenyl" means a straight or branched hydrocarbon radical having from 2 to 12 carbon atoms unless otherwise specified and having at least one double bond in the carbon atom chain and includes, for example, 1-ethene, 1-propene, 2-methyl-1-propene, 1-butene, 2-butene, 1-pentene, 2-pentene, 2-methyl-1-butene, 3-methyl-1-butene, 3-methyl-2-butene, 1-hexene, 1-heptene,
25 1-octene, 1-nonene, 1-decene, 1-undecene, 1-dodecene, and the like.

 The term "alkynyl" means a straight or branched hydrocarbon radical having from 2 to 12 carbon atoms unless otherwise specified and having at least one triple bond in the carbon atom chain and includes, for example, 1-ethyne, 1-propyne, 1-butyne, 3-methyl-1-butyne, 1-pentyne, 2-pentyne, 1-hexyne, and the
30 like.

 The term "cycloalkyl" means a saturated hydrocarbon ring which contains from 3 to 12 carbon atoms unless otherwise specified, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and adamantyl.

-75-

The phrase "lower cycloalkyl" means a saturated hydrocarbon ring which contains from 3 to 8 carbon atoms unless otherwise specified and includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.

5 "Halogen" is fluorine, chlorine, bromine, or iodine.

Some of the analgesics, antiepileptics having pain alleviating properties, and endothelin antagonists related to the invention, including compounds of Formulas I through VI, are capable of further forming nontoxic pharmaceutically acceptable acid addition and/or base salts. All of these forms are within the scope
10 of the present invention.

Pharmaceutically acceptable acid addition salts of the analgesics, antiepileptics having pain alleviating properties, and endothelin antagonists related to the invention, including compounds of Formulas I through VI, include salts derived from inorganic acids such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydriodic, hydrofluoric, phosphorous, and the like, as well
15 as the salts derived from organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanolic acids, hydroxy alkanolic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc. Such salts thus include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, trifluoroacetate, propionate, caprylate, isobutyrate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, phthalate, benzenesulfonate, toluenesulfonate, phenylacetate, citrate, lactate, maleate,
20 tartrate, methanesulfonate, and the like. Also contemplated are salts of amino acids such as arginate and the like and gluconate, galacturonate (see, for example, Berge S.M. et al., "Pharmaceutical Salts," *Journal of Pharmaceutical Science* 1977;66:1-19).
25

The acid addition salts of said basic compounds are prepared by contacting
30 the free base form with a sufficient amount of the desired acid to produce the salt in the conventional manner.

Pharmaceutically acceptable base addition salts are formed with metal cations, such as alkali and alkaline earth metal cations or amines such as organic

-76-

amines. Examples of metals used as cations are sodium, potassium, magnesium, calcium, and the like. Examples of suitable amines are N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, for example Berge S.M., Supra., 1977).

The base addition salts of said acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner.

Certain of the compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms, including hydrated forms, are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention.

Certain of the compounds of the present invention, possess one or more chiral centers and each center may exist in the R or S configuration. The present invention includes all enantiomeric and epimeric forms as well as the appropriate diastereomeric mixtures thereof.

MATERIALS AND METHODS

The method of Jarvis et al. is one method used to test the pain alleviating effects of the combinations of the instant invention and is hereby incorporated by reference (Jarvis M.F., Wessale J.L., Zhu C.Z., et al., *Eur. J. Pharmacol.* 2000;388:29-35).

A method for testing the novel combinations of the invention for pain alleviating activity in patients suffering from static or dynamic allodynia—forms of diabetic peripheral neuropathy—is described in Field M.J., Hughes J., Singh L., *Pain* 1999;80:391-398, which is hereby incorporated by reference.

Static and Dynamic Allodynia Methods:

1. *Animals*

Male Sprague-Dawley rats (175-200 g), obtained from Bantin and Kingman (Hull, UK), were housed in groups of six under a 12:12 hours/hours light-dark cycle (lights on at 07:00 hours) with food and water

-77-

ad libitum. All experiments were carried out by an observer unaware of drug treatments.

2. *Development of diabetes in the rat*

Diabetes was induced by a single i.p. injection of streptozocin at a dose of 50 mg/kg. Control animals received a similar administration of isotonic saline.

3. *Evaluation of static allodynia*

Static allodynia was measured using Semmes-Weinstein von Frey hairs (Stoelting, Wood Dale, IL). The animals were habituated to wire mesh bottom cages prior to the start of the experiment. Static allodynia was evaluated by application of von Frey hairs in ascending order of force (0.7, 1.2, 1.5, 2, 3.6, 5.5, 8.5, 11.8, 15.1, and 29 g) to the plantar surface of the rat's right hind paw. Each von Frey hair was applied to the paw for 6 seconds, or until a withdrawal response occurred. Once a withdrawal response was established, the paw was retested, starting with the next descending von Frey hair until no response occurred. The highest force of 29 g lifted the paw, as well as elicited a response, and thus represented the cut off point. The lowest amount of force required to elicit a response was recorded as PWT in grams.

4. *Evaluation of dynamic allodynia*

The animals are habituated to wire mesh bottom cages prior to the start of the experiment. Care is taken to perform this procedure in fully habituated rats that are not active to avoid recording general motor activity. Dynamic allodynia is assessed by lightly stroking the plantar surface of the rat's right hind paw with a cotton bud. Latency to paw withdrawal is noted. At least three measurements are taken at each time point. If no reaction is exhibited within 15 seconds, the procedure is terminated, and animals are assigned this withdrawal time. Thus 15 seconds effectively represents no withdrawal. A withdrawal response is often accompanied by repeated flinching or licking of the paw. Animals are only selected for drug studies if they exhibit a withdrawal time of 8 seconds or less.

-78-

5. *Development of hyperglycemia and the static component (and dynamic component) of streptozocin-induced mechanical allodynia*

Withdrawal thresholds to von Frey hairs were assessed on various days after the induction of diabetes. Animals with static allodynia were defined as those responding to 3.63 g or a lower strength von Frey hair.

(Withdrawal latencies to a cotton bud stimulus is also assessed on various days after the induction of diabetes. The same group of rats may be used to assess both withdrawal latencies and withdrawal thresholds. Animals with dynamic allodynia are defined as animals responding to the cotton stimulus within 8 seconds of stroking.) Blood glucose levels were measured in the same animals after each day of testing, using a Glucotrend meter and test strips (Boehringer Mannheim, Lewes, UK) to examine the development of hyperglycemia. Vehicle-treated controls were also examined for blood glucose levels on the same day.

6. *Evaluation of the effect of compounds on static allodynia (and dynamic allodynia)*

The antiallodynic potential of a compound administered alone was examined in streptozocin-treated animals once dynamic and static allodynia had developed. Baseline paw withdrawal thresholds to von Frey hairs (or paw withdrawal latencies to a cotton bud) were determined on each test day before drug administration. After drug administration, animals were re-evaluated using von Frey hairs (or cotton bud) at 0.5, 1, 2, and up to 4 hours. Using this data, the time point postdose for peak activity of each individual compound were determined. The antiallodynic potential of a combination of the invention was then determined at the time point postdose that was expected to show peak activity for the combination.

7. *Drugs*

Streptozocin was purchased from Aldrich (UK). All compounds were dissolved in normal saline and administered orally. Drug administrations were made in a volume of 1 mL/kg.

8. *Data analysis*

Data obtained from the static allodynia studies were analyzed using a one-way ANOVA followed by a Dunnett's t-test and an individual Mann-

-79-

Whitney *U*-test. In each case the drug-treated groups were compared with the appropriate vehicle-treated group. (Data obtained from dynamic allodynia studies is also analyzed using these methods.)

9. *Development of streptozocin-induced static (and dynamic) allodynia*

5 The development of streptozocin-induced static allodynia followed distinct time courses. Static allodynia could be detected from Day 4 post-streptozocin and was present in the majority of animals within 10 days, with animals demonstrating a PWT to the previously innocuous 3.63 g or lower force. (Dynamic allodynia follows a slower onset. It is not exhibited
10 by all animals, with approximately 60% displaying a PWT of 8 seconds or less at 18 days post-streptocozin.) Vehicle-treated control animals exhibited a consistent PWT of 8.5 to 11.75 g to von Frey stimulus. (Vehicle-treated animals find the cotton bud stimulus innocuous throughout the dynamic allodynia studies.) Vehicle-treated animals had
15 consistent blood glucose levels, similar to baseline values, throughout the experiment. Streptozocin-treated animals had elevated blood glucose values from the first day of testing, Day 4 post-streptozocin dose.

The static allodynia method of Field et al., was used in Tests 1 and 2, and Examples 1 through 3 below.

20

TEST 1

Gabapentin was administered orally alone at doses of 10, 30, or 100 mg/kg of rat body weight, and PWT was determined at 1 hour postdose, the time point of peak activity for this compound. The results are illustrated in Figure 1 with the line ●.


25

TEST 2


The compound of formula (1) was administered orally alone at doses of 3, 10, or 30 mg/kg of rat body weight, and PWT was determined at 1 hour postdose, the time point of peak activity for this compound. The results are illustrated in Figure 1 with the line ▲.

-80-


EXAMPLE 1

A combination of gabapentin and the compound of formula (1) at a 1:1 ratio, respectively, was administered orally at total doses (dose of gabapentin + dose of the compound of formula (1) of 2 mg/kg (1 mg/kg + 1 mg/kg, respectively), 6 mg/kg (3 mg/kg + 3 mg/kg, respectively), 20 mg/kg (10 mg/kg + 10 mg/kg, respectively), or 40 mg/kg (20 mg/kg + 20 mg/kg, respectively), and PWT was determined at 1 hour postdose. The results are illustrated in Figure 2 with the line . For comparison purposes, the results from Tests 1 and 2 are also illustrated in Figure 2.

EXAMPLE 2

A combination of gabapentin and the compound of formula (1) at a 3:1 ratio, respectively, was administered orally at total doses (dose of gabapentin + dose of the compound of formula (1) of 4 mg/kg (3 mg/kg + 1 mg/kg, respectively), 12 mg/kg (9 mg/kg + 3 mg/kg, respectively), 28 mg/kg (21 mg/kg + 7 mg/kg, respectively), or 40 mg/kg (30 mg/kg + 10 mg/kg, respectively), and PWT was determined at 1 hour postdose. The results are illustrated in Figure 3 with the line . For comparison purposes, the results from Tests 1 and 2 are also illustrated in Figure 3.

EXAMPLE 3

A combination of gabapentin and the compound of formula (1) at a 10:1 ratio, respectively, was administered orally at total doses (dose of gabapentin + dose of the compound of formula (1) of 11 mg/kg (10 mg/kg + 1 mg/kg, respectively) or 33 mg/kg (30 mg/kg + 3 mg/kg, respectively), and PWT was determined at 1 hour postdose. The results are illustrated in Figure 4 with the line . For comparison purposes, the results from Tests 1 and 2 are also illustrated in Figure 4.

The results of Tests 1 and 2 and Examples 1 through 3 are illustrated in Figures 1 through 4 as described above. All data illustrated in the figures were determined at 1 hour postdose. In Figure 1, a dose-response curve for gabapentin administered alone shows that at a dose of 10 mg/kg, gabapentin had little or no effect on static allodynia, while at doses of 30 and 100 mg/kg, gabapentin effected

-81-

essentially a complete reversal of static allodynia. (As mentioned above, the presence of complete static allodynia is characterized by a PWT of ≤ 3.63 g, while the absence of static allodynia is characterized by a PWT of ≥ 8.5 g.) Also in Figure 1 is a dose-response curve for the compound of formula (1) administered alone. This curve shows that at a dose of 3 mg/kg, the compound of formula (1) had little or no effect on static allodynia, while at doses of 10 and 30 mg/kg, the compound of formula (1) effected a partial (about 50%) reversal of static allodynia.

In Figure 2, a dose-response curve for a combination of gabapentin and the compound of formula (1) administered at a ratio of 1:1 (weight:weight), respectively, shows that at a total dose of 2 or 6 mg/kg, the combination had little or no effect on static allodynia, while at total doses of 20 or 40 mg/kg, the combination effected partial reversal of static allodynia. Also in Figure 2 for comparison purposes are the dose-response curves described for Figure 1.

In Figure 3, a dose-response curve for a combination of gabapentin and the compound of formula (1) administered at a ratio of 3:1 (weight:weight), respectively, shows that at a total dose of 4 mg/kg, the combination had little or no effect on static allodynia, while at total doses of 12 or 28 mg/kg, the combination effected partial reversal of static allodynia. Further at a total dose of 40 mg/kg, this combination effected a complete reversal of static allodynia. Also in Figure 3, for comparison purposes, are the dose-response curves described for Figure 1.

In Figure 4, a dose-response curve for a combination of gabapentin and the compound of formula (1) administered at a ratio of 10:1 (weight:weight), respectively, shows that at a total dose of 11 mg/kg, the combination had little or no effect on static allodynia, while at a total dose of 33 mg/kg, the combination effected partial reversal of static allodynia. Also in Figure 4, for comparison purposes, are the dose-response curves described for Figure 1.

The results illustrated in Figures 2 through 4 show that the combinations of the present invention are effective at reversing static allodynia, and are thus useful for the treatment of pain.

Alternatively, a rat carrageenan-induced thermal hyperalgesia model may be used to determine pain alleviating effects as follows.

-82-

Animals

Male Sprague-Dawley rats (200-250 g, Sasco Laboratories) are used. Rats are group housed 5/cage on a 12-hour light:dark cycle with free access to food and water. Rats receive only one dose of a drug or drug combination. All drugs are administered orally by gavage.

Experimental Design

Dose-effect curves are first determined for (1) an endothelin antagonist by itself, (2) antiepileptic compound having pain alleviating properties by itself, and/or (3) an analgesic (e.g., naproxen) by itself. The ED₅₀ value and 95% confidence limits of each agent is determined, as is the time to peak effect. After determination of these values, dose effect curves are generated for the endothelin antagonist administered in a fixed dose ratio with the antiepileptic compound having pain alleviating properties and/or the analgesic; the drugs are administered so that their peak effects are coincident. ED₅₀ values and 95% confidence limits are then determined for the drugs in combination.

Measures of Antinociception

Carrageenan-induced thermal hyperalgesia: Rats are acclimated to a testing chamber whose glass floor is maintained at 25°C. Thirty minutes later, a high intensity beam of light is focused through the glass on the ventral surface of each hindpaw, and the latency to reflex withdrawal of the paw from the light beam is measured to the nearest 0.1 second. This latency is termed the paw flick latency (PFL). Two measurements of PFL spaced 20 minutes apart are made for each paw, and the second measurement is taken as the baseline response latency. After determination of baseline PFL, 100 µL of 2% lambda-carrageenan is injected in the plantar surface of one hindpaw and the animal is returned to the testing chamber. Two hours later, when thermal hyperalgesia is maximal and stable, either vehicle, (1) the endothelin antagonist by itself, (2) the antiepileptic compound having pain alleviating properties by itself, (3) the analgesic by itself,

-83-

or (4) a combination of the invention is administered by gavage. Response latencies for the ipsilateral and contralateral hindpaws are then re-determined 15, 30, 45, 60, 90, and 120 minutes later. Data for further analysis are taken 120 minutes after oral dosing.

5 **Statistical Analysis**

10 Data are expressed as the mean \pm SEM. Two-way analyses of variance for repeated measures is used to compare the effects of drug to that of vehicle. Dose-effect lines for each compound administered by itself are constructed using individual data and fitted with least squares linear regression analysis to determine ED₅₀ values and 95% confidence limits. A similar analysis is conducted for the compounds in combination using the total dose administered. Since parallel dose-effect lines are obtained for each compound administered by itself, and the combination of the invention, then a parallel line assay is conducted as described by Tallarida (Tallarida, 1992; Tallarida et al; 1989). This analysis compares the position of the experimentally-derived dose-effect line for the combination to the position of the theoretical dose-additive line. A significant shift to the left or the right of the theoretical dose-additive line indicates that the compounds interact in a supra-additive (synergistic) or an infra-additive manner (antagonistic), respectively.

20 The amount of the active ingredients in the combinations will vary depending on the mammal to which the combinations are administered, the type of pain to be treated, other active ingredients present, etc. Generally, the amount of the endothelin receptor antagonist(s) and the other active compound(s) for a given composition and dosage form can be readily determined employing routine procedures.

25 The combinations of the present invention can be prepared and administered in a wide variety of oral and parenteral dosage forms. Thus, the combinations of the present invention can be administered by injection, that is, intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, 30 or intraperitoneally. Also, the combinations of the present invention can be

-84-

administered by inhalation, for example, intranasally. Additionally, the combinations of the present invention can be administered transdermally. It will be obvious to those skilled in the art that the following dosage forms may comprise as the active components, a compound of Formula V or Formula VI, or a corresponding pharmaceutically acceptable salt thereof and from one to three compounds selected from the group consisting of antiepileptic compounds having pain alleviating properties and analgesics, or pharmaceutically acceptable salts thereof.

For preparing pharmaceutical compositions from the combinations of the present invention, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.

In powders, the carrier is a finely divided solid which is in a mixture with the finely divided active component(s).

In tablets, the active component(s) is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.

The powders and tablets preferably contain from 5% to about 70% of the active combinations. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound(s) with encapsulating material as a carrier providing a capsule in which the active component(s), with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.

For preparing suppositories, a low melting wax, such as a mixture of fatty acid glycerides or cocoa butter, is first melted and the active component(s) is dispersed homogeneously therein, as by stirring. The molten homogenous mixture

-85-

is then poured into convenient sized molds, allowed to cool, and thereby to solidify.

Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water propylene glycol solutions. For parenteral injection,
5 liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.

Aqueous solutions suitable for oral use can be prepared by dissolving the active component(s) in water and adding suitable colorants, flavors, stabilizing, and thickening agents as desired.

10 Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component(s) in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.

Also included are solid form preparations which are intended to be
15 converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.

20 The pharmaceutical preparation is preferably in unit dosage form. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component(s). The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit
25 dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.

The quantity of each active component in a unit dose preparation may be varied or adjusted from 1 to 1000 mg, preferably 10 to 100 mg according to the particular application and the potency of each active component. The composition
30 can, if desired, also contain other compatible therapeutic agents.

Co-administration of an endothelin receptor antagonist and from one to three compounds selected from the group consisting of antiepileptic compounds having pain alleviating properties and analgesics may comprise simultaneous or

-86-

sequential administration of each pharmaceutically active compound that has been independently formulated by itself. Alternatively, co-administration may comprise administration of an endothelin receptor antagonist and from one to three compounds selected from the group consisting of antiepileptic compounds having pain alleviating properties and analgesics wherein the pharmaceutically active compounds of the combination have been combined in a single formulation. Further, co-administration may comprise a combination of these two approaches wherein certain pharmaceutically active compounds are formulated together and others are independently formulated by themselves, and the formulations are administered simultaneously or sequentially.

In therapeutic use as agents for the treatment of pain, the analgesics, antiepileptic compounds having pain alleviating properties, and endothelin antagonist compounds utilized in the pharmaceutical method of this invention can each be administered at the initial dosage of about 1 to about 100 mg/kg daily. A daily dose range of about 1 to about 75 mg/kg is preferred. Further, a concentration range of the antiepileptic and/or analgesic between 1% and 99% and a complementary concentration range of endothelin antagonist compound between 99% and 1% of the 100% total of the combination of active ingredients is preferred. The dosages, however, may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound being employed. Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages that are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstance is reached. For convenience, the total daily dosage may be divided and administered in portions during the day if desired.

An example of an oral formulation follows.

-87-

EXAMPLE 4

Tablet Formulation:

Ingredient	Amount (mg)
<i>4-(7-ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)-phenyl]-2H-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide, potassium salt</i>	25
Gabapentin	25
Lactose	50
Cornstarch (for mix)	10
Cornstarch (paste)	10
Magnesium stearate (1%)	5
Total	125

The *1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide, potassium salt*, gabapentin, lactose, and cornstarch (for mix) are blended to uniformity. The cornstarch (for paste) is suspended in 200 mL of water and heated with stirring to form a paste. The paste is used to granulate the mixed powders. The wet granules are passed through a No. 8 hand screen and dried at 80°C. The dry granules are lubricated with the 1% magnesium stearate and pressed into a tablet. Such tablets can be administered to a human from one to four times a day for treatment of pain.


Having described the present invention above, various embodiments of the invention are hereforth claimed.

-88-

What is claimed is:


1. A combination effective for alleviating pain comprising a pain alleviating effective amount of an endothelin antagonist or a pharmaceutically acceptable salt thereof and from one to three compounds independently selected from the group consisting of antiepileptic compounds having pain alleviating properties and analgesics, and pharmaceutically acceptable salts thereof.

2. The combination of Claim 1 wherein the antiepileptic compound having pain alleviating properties is a compound of Formula I




wherein R_1 is hydrogen or a lower alkyl; n is an integer of from 4 to 6; and the cyclic ring is optionally substituted by lower alkyl or lower cycloalkyl, and the pharmaceutically acceptable salts thereof.

3. The combination of Claim 1 wherein the antiepileptic compound having pain alleviating properties is gabapentin.
4. The combination of Claim 1 wherein the antiepileptic compound having pain alleviating properties is a compound of Formula II



wherein R_{11} is a straight or branched alkyl of from 1 to 6 carbon atoms, phenyl, or cycloalkyl having from 3 to 6 carbon atoms; R_{12} is hydrogen or methyl; and R_{13} is hydrogen, methyl, or carboxyl; or an individual diastereomeric or enantiomeric isomer thereof; or a pharmaceutically acceptable salt thereof.

5. The combination according to Claim 1 wherein the antiepileptic compound having pain alleviating properties is a compound of Formula



or a pharmaceutically acceptable salt thereof wherein:

n is an integer of from 0 to 2;

m is an integer of from 0 to 3;

R is sulfonamide,

amide,

phosphonic acid,

heterocycle,

sulfonic acid, or

hydroxamic acid;

R₁ to R₁₄ are each independently selected from hydrogen or straight or

branched alkyl of from 1 to 6 carbons, unsubstituted or substituted


benzyl or phenyl which substituents are selected from halogen,

alkyl, alkoxy, hydroxy, carboxy, carboalkoxy, trifluoromethyl, and

nitro;

A' is a bridged ring selected from

-90-



wherein


is the point of attachment;

- 5 Z₁ to Z₄ are each independently selected from hydrogen and methyl;
 o is an integer of from 1 to 4; and
 p is an integer of from 0 to 2 with the proviso that in formula (1), R is not
 -SO₃H when m is 2 and n is 1.

- 10 6. The combination of Claim 1 wherein the antiepileptic compound having
 pain alleviating properties is gabapentin.
7. The combination of Claim 1 wherein the antiepileptic compound having
 pain alleviating properties is pregabalin.
- 15 8. The combination of Claim 1 wherein the antiepileptic compound having
 pain alleviating properties is 3-(1-aminomethyl-cyclohexylmethyl)-4H-
 [1,2,4]oxadiazol-5-one hydrochloride.

-91-


9. The combination of Claim 1 wherein the endothelin antagonist is selected from a compound of Formula V



V

or a pharmaceutically acceptable acid addition or base salt thereof
wherein:

R₂ is H,



alkyl of from 1 to 7 carbons, (CH₂)_n-cycloalkyl of from 3 to
8 carbons;

R_a and R_c are each 1 to 5 substituents and R_b is from 1 to 4 substituents

independently selected from:

hydrogen,

alkyl of from 1 to 7 carbons,

alkenyl of from 2 to 7 carbons,

alkynyl of from 2 to 7 carbons,

cycloalkyl of from 3 to 8 carbons,

phenyl,

C(O)-phenyl,

methylenedioxy,

ethylenedioxy,

OR,

NRR₁,

SR₁,

NO₂,

-92-

N₃,

COR,

CO₂R,

Cl,

5

Br,

F,

I,

CONRR₁,SO₂NRR₁,

10

SO₂R,

CN,

CF₃,CF₂CF₃,

CHO,

15

OCOR,

B(OH)₂,NH(CH₂)_pCO₂R,S(CH₂)_pCO₂R,O(CH₂)_pCO₂R,

20

O(CH₂)_pOR,NH(CH₂)_pOR,S(CH₂)_pOR, orwherein R and R₁ are each independently selected from

hydrogen,

25

alkyl of from 1 to 6 carbon atoms,

alkenyl of from 2 to 7 carbon atoms,

alkynyl of from 2 to 7 carbon atoms,


cycloalkyl of from 3 to 8 carbon atoms,

-93-

phenyl or benzyl wherein the phenyl or benzyl ring is substituted by one or more hydrogen, methoxy, and methylenedioxy substituents;

R_d is H, CO_2R , SO_3R , PO_3R , $\text{B}(\text{OH})_2$, CONRR_1 , SO_2NRR_1 ,

$\text{C}(\text{O})\text{NH}\text{SO}_2\text{R}_1$,




n is an integer of from 0 to 2;

p is an integer of from 1 to 4;

-- indicates a single or double bond; and

X is $(\text{CH}_2)_n$, O, NR , or $\text{S}(\text{O})_n$.

10. The combination of Claim 1 wherein the endothelin antagonist is selected from a compound of Formula VI



VI

wherein

--- denotes an optional bond;

n is 0 to 4;

R_a is hydrogen, alkyl of 1-4 carbon atoms or cycloalkyl, phenyl or


naphthyl, in which the phenyl or naphthyl group is substituted by methylenedioxy and further unsubstituted or substituted by one or more substituents selected from the group consisting of halogen, alkyl of 1-6 carbon atoms, OR, NRR^1 , SR, NO_2 , N_3 , COR, CO_2R , CONRR^1 , SO_2NRR^1 , SO_2R , CN, CF_3 , CF_2CF_3 , CHO, OCOCH_3 , $\text{B}(\text{OH})_2$, phenyl, $\text{NH}(\text{CH}_2)_m\text{CO}_2\text{R}$, $\text{S}(\text{CH}_2)_m\text{CO}_2\text{R}$,

-94-

$O(CH_2)_mCO_2R$, $O(CH_2)_mOR$, $NH(CH_2)_mOR$ and $S(CH_2)_mOR$,

in which m is 1, 2 or 3, and R and R^1 are each independently hydrogen, alkyl of 1-4 carbon atoms, phenyl or benzyl;

R_b is hydrogen, CO_2R^2 ,



SO_3R , PO_3H , $B(OH)_2$, $CONR^1R^2$, $SO_2NR^1R^2$, or



in which R^1 is as defined above and R^2 is hydrogen, alkyl of 1-6 carbon atoms, CF_3 , $-CF_2CF_3$, phenyl or benzyl in which phenyl or the phenyl portion of the benzyl group is unsubstituted or substituted by one or more substituents as defined above;

R_c is $S(O)_p$ -phenyl, in which p is 0, 1 or 2, and phenyl is unsubstituted or substituted by one or more substituents selected from the group consisting of halogen, OR , NRR^1 , SR , NO_2 , N_3 , COR , CO_2R , $CONRR^1$, SO_2NRR^1 , SO_2R , CN , CF_3 , CF_2CF_3 , CHO , $OCOCH_3$, $B(OH)_2$, methylenedioxy, $NH(CH_2)_mCO_2R$, $S(CH_2)_mCO_2R$, $O(CH_2)_mCO_2R$, $O(CH_2)_mOR$, $NH(CH_2)_mOR$ and $S(CH_2)_mOR$, in which m , R and R^1 are as defined above, and

R_d is one to four independent substituents selected from hydrogen, alkyl of 1-7 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, cycloalkyl, phenyl, $C(O)$ -phenyl, $X(CH_2)_n$ -phenyl, $X-(CH_2)_n$ -naphthyl, in which X is 0, NH or $S(O)_p$, methylenedioxy, OR , NRR^1 , SR , NO_2 , N_3 , COR , CO_2R , $CONRR^1$, SO_2NRR^1 , SO_2R , CN , CF_3 , CF_2CF_3 , CHO , $OCOCH_3$, $B(OH)_2$, phenyl, $NH(CH_2)_mCO_2R$, $S(CH_2)_mCO_2R$,

-95-

$O(CH_2)_mCO_2R$, $O(CH_2)_mOR$, $NH(CH_2)_mOR$, $S(CH_2)_mOR$, in which m is 1, 2 or 3 and R and R^1 are each independently hydrogen, alkyl of 1-4 carbon atoms, phenyl or benzyl and where n and p are as defined above and phenyl is unsubstituted or substituted as defined above, or a pharmaceutically acceptable acid addition or base salt thereof.

11. The combination of Claim 1 wherein the endothelin antagonist is selected from:

4-Benzo[1,3]dioxol-5-yl-2-methyl-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

4-Benzo[1,3]dioxol-5-yl-2-benzo[1,3]dioxol-5-ylmethyl-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

4-Benzo[1,3]dioxol-5-yl-2-benzyl-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

4-Benzo[1,3]dioxol-5-yl-2-(4-methoxy-benzyl)-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

4-Benzo[1,3]dioxol-5-yl-1,1-dioxo-2-(3,4,5-trimethoxy-benzyl)-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

4-Benzo[1,3]dioxol-5-yl-2-(2-carboxymethoxy-4-methoxy-benzyl)-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

4-Benzo[1,3]dioxol-5-yl-2-(6-chloro-benzo[1,3]dioxol-5-ylmethyl)-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

4-Benzo[1,3]dioxol-5-yl-2-(7-methoxy-benzo[1,3]dioxol-5-ylmethyl)-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

2-Benzo[1,3]dioxol-5-ylmethyl-4-(3,4-dimethoxy-phenyl)-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

-96-

2-Benzo[1,3]dioxol-5-ylmethyl-1,1-dioxo-4-(3,4,5-trimethoxy-phenyl)-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

N-(4-Benzo[1,3]dioxol-5-yl-2-benzo[1,3]dioxol-5-ylmethyl-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carbonyl)-benzenesulfonamide;

2-Benzo[1,3]dioxol-5-ylmethyl-4-(3-methoxy-phenyl)-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

4-Benzo[1,3]dioxol-5-yl-2-benzo[1,3]dioxol-5-ylmethyl-6,7-dimethoxy-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

4-Benzo[1,3]dioxol-5-yl-2-benzo[1,3]dioxol-5-ylmethyl-6-methoxy-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

8-Benzo[1,3]dioxol-5-yl-6-benzo[1,3]dioxol-5-ylmethyl-5,5-dioxo-5,6-dihydro-1,3-dioxo-5 λ^6 -thia-6-aza-cyclopenta[b]naphthalene-7-carboxylic acid;

4-(Benzo[1,3]dioxol-5-ylsulfanyl)-2-methyl-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

2-Benzo[1,3]dioxol-5-ylmethyl-4-(benzo[1,3]dioxol-5-ylsulfanyl)-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

4-(Benzo[1,3]dioxol-5-ylsulfanyl)-2-benzyl-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

4-(Benzo[1,3]dioxol-5-ylsulfanyl)-2-(4-methoxy-benzyl)-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

4-(Benzo[1,3]dioxol-5-ylsulfanyl)-1,1-dioxo-2-(3,4,5-trimethoxy-benzyl)-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

4-(Benzo[1,3]dioxol-5-ylsulfanyl)-2-(carboxymethoxy-4-methoxy-benzyl)-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

-97-

4-(Benzo[1,3]dioxol-5-ylsulfanyl)-2-(6-chloro-benzo[1,3]dioxol-5-ylmethyl)-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

5 4-(Benzo[1,3]dioxol-5-ylsulfanyl)-2-(7-methoxy-benzo[1,3]dioxol-5-ylmethyl)-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

2-Benzo[1,3]dioxol-5-ylmethyl-4-(3,4-dimethoxy-phenylsulfanyl)-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

10 2-Benzo[1,3]dioxol-5-ylmethyl-1,1-dioxo-4-(3,4,5-trimethoxy-phenylsulfanyl)-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

N-(4-Benzo[1,3]dioxol-5-ylsulfanyl-2-benzo[1,3]dioxol-5-ylmethyl-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carbonyl)-benzenesulfonamide;

15 2-Benzo[1,3]dioxol-5-ylmethyl-4-(3-methoxy-phenylsulfanyl)-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

2-Benzo[1,3]dioxol-5-ylmethyl-4-(benzo[1,3]dioxol-5-ylsulfanyl)-6,7-dimethoxy-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

20 2-Benzo[1,3]dioxol-5-ylmethyl-4-(benzo[1,3]dioxol-5-ylsulfanyl)-6-methoxy-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

6-Benzo[1,3]dioxol-5-ylmethyl-8-(benzo[1,3]dioxol-5-ylsulfanyl)-5,5-dioxo-5,6-dihydro-1,3-dioxo-5 λ^6 -thia-6-aza-cyclopenta[b]-naphthalene-7-carboxylic acid;

25 4-(Benzo[1,3]dioxol-5-ylsulfanyl)-2-isobutyl-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

2-Benzo[1,3]dioxol-5-ylmethyl-4-(benzo[1,3]dioxol-5-ylsulfanyl)-7-methoxy-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

-98-

2-Benzo[1,3]dioxol-5-ylmethyl-4-(2,3-dihydro-benzo[1,4]dioxin-6-ylsulfanyl)-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

4-(Benzo[1,3]dioxol-5-ylsulfanyl)-2-(2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

4-(Benzo[1,3]dioxol-5-ylsulfanyl)-2-cyclohexylmethyl-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

2-Benzo[1,3]dioxol-5-yl-4-(benzo[1,3]dioxol-5-ylsulfanyl)-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

2-Benzo[1,3]dioxol-5-yl-4-(benzo[1,3]dioxol-5-ylsulfanyl)-6,7-dimethoxy-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

2,4-Bis-benzo[1,3]dioxol-5-yl-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

2,4-Bis-benzo[1,3]dioxol-5-yl-6,7-dimethoxy-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

4-Benzo[1,3]dioxol-5-yl-2-(2-chloro-benzyl)-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

2-Benzo[1,3]dioxol-5-ylmethyl-4-(4-chloro-2,6-dimethoxyphenyl)-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

4-(Benzo[1,3]dioxol-5-ylsulfanyl)-2-(2-chloro-benzyl)-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

2-Benzo[1,3]dioxol-5-ylmethyl-4-(4-chloro-2,6-dimethoxyphenylsulfanyl)-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

4-(Benzo[1,3]dioxol-5-yl)-2-isobutyl-1,1-dioxo-1,2-dihydro-1 λ^6 -benzo[e][1,2]thiazine-3-carboxylic acid;

-99-

2-Benzo[1,3]dioxol-5-ylmethyl-4-(benzo[1,3]dioxol-5-yl)-7-methoxy-1,1-dioxo-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid;

2-Benzo[1,3]dioxol-5-ylmethyl-4-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-1,1-dioxo-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid;

4-(Benzo[1,3]dioxol-5-yl)-2-(2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-1,1-dioxo-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid;

4-(Benzo[1,3]dioxol-5-yl)-2-cyclohexylmethyl-1,1-dioxo-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid;

1-Benzo[1,3]dioxol-5-yl-3-phenylsulfanyl-1*H*-indole-2-carboxylic acid;

1-Benzo[1,3]dioxol-5-ylmethyl-5,6-dimethoxy-3-(3-methoxy-phenylsulfanyl)-1*H*-indole-2-carboxylic acid;

1-Benzo[1,3]dioxol-5-ylmethyl-3-(3-methoxy-phenylsulfanyl)-1*H*-indole-2-carboxylic acid;

1-Benzyl-3-(3-methoxy-phenylsulfanyl)-1*H*-indole-2-carboxylic acid;

1-Benzo[1,3]dioxol-5-ylmethyl-3-(benzo[1,3]dioxol-5-ylsulfanyl)-1*H*-indole-2-carboxylic acid;

5-Benzo[1,3]dioxol-5-ylmethyl-7-(3-methoxy-phenylsulfanyl)-5*H*-[1,3]dioxolo[4,5-*f*]indole-6-carboxylic acid;

5-(7-Methoxy-benzo[1,3]dioxol-5-ylmethyl)-7-(3-methoxy-phenylsulfanyl)-5*H*-[1,3]dioxolo[4,5-*f*]indole-6-carboxylic acid;

5-Benzo[1,3]dioxol-5-ylmethyl-7-(3,4-dimethoxy-phenylsulfanyl)-5*H*-[1,3]dioxolo[4,5-*f*]indole-6-carboxylic acid;

7-(3,4-Dimethoxy-phenylsulfanyl)-5-(7-methoxy-benzo[1,3]dioxol-5-ylmethyl)-5*H*-[1,3]dioxolo[4,5-*f*]indole-6-carboxylic acid;

1-Benzo[1,3]dioxol-5-ylmethyl-3-(3-methoxy-phenylsulfanyl)-6-propoxy-1*H*-indole-2-carboxylic acid;

5,6-Dimethoxy-1-(7-methoxy-benzo[1,3]dioxol-5-ylmethyl)-3-(3-methoxy-phenylsulfanyl)-1*H*-indole-2-carboxylic acid;

-100-

5,6-Dimethoxy-1-(4-methoxy-benzyl)-3-(3-methoxy-phenylsulfanyl)-1*H*-indole-2-carboxylic acid;

1-Benzo[1,3]dioxol-5-ylmethyl-5-benzyloxy-6-methoxy-3-(3-methoxy-phenylsulfanyl)-1*H*-indole-2-carboxylic acid;

5 1-Benzo[1,3]dioxol-5-ylmethyl-5,6-dimethoxy-3-(3,4,5-trimethoxy-phenylsulfanyl)-1*H*-indole-2-carboxylic acid;

1-Benzo[1,3]dioxol-5-ylmethyl-3-(benzo[1,3]dioxol-5-ylsulfanyl)-6-benzyloxy-5-methoxy-1*H*-indole-2-carboxylic acid;

1-(2-Carboxymethoxy-4-methoxy-benzyl)-5,6-dimethoxy-3-(3-methoxy-phenylsulfanyl)-1*H*-indole-2-carboxylic acid;

10 1-Benzo[1,3]dioxol-5-ylmethyl-3-(benzo[1,3]dioxol-5-ylsulfanyl)-5,6-dimethoxy-1*H*-indole-2-carboxylic acid;

1-Benzo[1,3]dioxol-5-ylmethyl-3-(3,4,5-trimethoxy-phenylsulfanyl)-6-benzyloxy-5-methoxy-1*H*-indole-2-carboxylic acid;

15 5-Benzo[1,3]dioxol-5-ylmethyl-7-(3,4,5-trimethoxy-phenylsulfanyl)-5*H*-[1,3]dioxolo[4,5-*f*]indole-6-carboxylic acid;

5-Benzo[1,3]dioxol-5-ylmethyl-7-(benzo[1,3]dioxol-5-ylsulfanyl)-5*H*-[1,3]dioxolo[4,5-*f*]indole-6-carboxylic acid;

20 [2*S*-(2*Alpha*,3*beta*,4*alpha*)]-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)-3-pyrrolidinecarboxylic acid;

3-Pyrrolidinecarboxylic acid, 4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)-, sodium salt, (2*R*,3*R*,4*S*)-rel-;

25 N-[6-(2-Hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(1*H*-tetrazol-5-yl)-4-pyridinyl]-4-pyrimidinyl]-5-(1-methylethyl)-2-pyridinesulfonamide;

5-(Dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide;

30 4-(1,1-Dimethylethyl)-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]benzenesulfonamide;

-101-

Benzenesulfonamide, 4-(1,1-dimethyl)-N-[6-(2-hydroxyethoxy)-5-(3-methoxyphenoxy)-4-pyrimidinyl]-;

[N-cis-2,6-Dimethylpiperidinocarbonyl-L-.gamma.-methylleucyl-D-1-methoxycarbonyltryptophanyl-D-norleucine];

5 [5S-[5Alpha,6beta,7alpha(R*)]]-5-(1,3-benzodioxol-5-yl)-2-butyl-7-[2-(2-carboxypropyl)-4-methoxyphenyl]-6,7-dihydro-5H-cyclopenta[b]pyridine-6-carboxylic acid;

5S-(5alpha,6beta,7alpha(R*)))-2-butyl-5-(1,3-benzodioxol-5-yl)-7-((2-carboxypropyl)-4-methoxyphenyl)-6-dihydro-5H-cyclopenta(b)pyridine-6-carboxylic acid (J-104120);

10 [5S-[5Alpha,6beta,7alpha(R*)]]-5-(1,3-benzodioxol-5-yl)-2-butyl-7-[2-(2-carboxypropyl)-4-methoxyphenyl]-6,7-dihydro-5H-cyclopenta[b]pyridine-6-carboxylic acid (L-753037);

(S)-Alpha-[(4,6-Dimethoxy-2-pyrimidinyl)oxy]-beta-methoxy-beta-phenyl benzenepropanoic acid;

15 Alpha-((4,6-dimethoxy-2-pyrimidinyl)oxy)-beta-methoxy-beta-phenyl-benzenepropanoic acid (LU-127043);

2-(4,6-Dimethoxypyrimidin-2-yloxy)-3-ethoxy-3,3-diphenylpropionic acid;

20 N-[6-(2-Hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(1H-tetrazol-5-yl)-4-pyridinyl]-4-pyrimidinyl]-5-methyl-2-pyridinesulfonamide;

2-Pyridinesulfonamide, N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(1H-tetrazol-5-yl)-4-pyridinyl]-4-pyrimidinyl]-5-methyl-;

25 27-O-3-[2-(3-Carboxy-acryloylamino)-5-hydroxyphenyl]-acryloyloxy myricerone;

30 N-[6-[2-[(5-Bromo-2-pyrimidinyl)oxy]ethoxy]-5-(4-methylphenyl)-4-pyrimidinyl]-4-(2-hydroxy-1,1-dimethylethyl)-benzenesulfonamide monosodium;

4-tert-Butyl-N-(5-(4-methylphenyl)-6-(2-(5-(3-thienyl)pyrimidin-2-yloxy)ethoxy)pyrimidin-4-yl)-benzenesulfonamide (T-0115);

-102-

Cyclo[4-oxo-4-(4-phenyl-1-piperazinyl)-L-2-aminobutanoyl-L-alpha-aspartyl-D-2-(2-thienyl)glycyl-L-leucyl-D-tryptophyl-D-alpha-aspartyl]disodium salt;

5 N-(4-Chloro-3-methyl-5-isoxazolyl)-2-[(6-methyl-1,3-benzodioxol-5-yl)acetyl]-3-thiophenesulfonamide;

3-Thiophenesulfonamide, N-(4-chloro-3-methyl-5-isoxazolyl)-2-[(6-methyl-1,3-benzodioxol-5-yl)acetyl]- (IPI-1040);

3-Thiophenesulfonamide, N-(4-chloro-3-methyl-5-isoxazolyl)-2-[(6-methyl-1,3-benzodioxol-5-yl)acetyl]- (IPI-1251); and

10 3-Thiophenesulfonamide, N-(4-chloro-3-methyl-5-isoxazolyl)-2-[(6-methyl-1,3-benzodioxol-5-yl)acetyl]- (TBC-11241).

12. The combination of Claim 1 wherein the endothelin receptor antagonist is 4-(7-ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2H-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide, or a
15 pharmaceutically acceptable salt thereof.

13. The combination of Claim 1 wherein the endothelin receptor antagonist is 4-(7-ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2H-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide, potassium salt.

14. The combination of Claim 1 wherein the the endothelin receptor antagonist
20 is 4-(3,5-dimethyl-phenyl)-1,1-dioxo-2-(2-trifluoromethyl-phenyl)-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof.

15. The combination of Claim 1 wherein the the endothelin receptor antagonist
25 is 4-(3,5-dimethyl-phenyl)-1,1-dioxo-2-(2-trifluoromethyl-phenyl)-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid.

16. The combination of Claim 1 wherein the analgesic is an NSAID.

-103-

17. The combination of Claim 1 wherein the analgesic is an NSAID selected from:

Naproxen;
Naproxen sodium;
5 Ibuprofen;
Acetaminophen;
Aspirin;
Sulindac;
Tolmetin;
10 Piroxicam;
Mefenamic acid;
Phenylbutazone;
Fenoprofen;
Ketoprofen;
15 Suprofen;
Diflunisal;
Celecoxib;
Meloxicam; and
(Z)-5-[[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]-
20 2-imino-4-thiazolidinone methanesulfonate (1:1).

18. The combination of Claim 1 wherein the analgesic is an NMDA receptor antagonist.

19. The combination of Claim 1 wherein the analgesic is an NMDA receptor antagonist selected from:

25 1H-Indole-2-carboxylic acid, 4,6-dichloro-3-[3-oxo-
3-(phenylamino)-1-propenyl]-, (E)- (GV-150526);
1-Piperidineethanol, .alpha.-(4-hydroxyphenyl)-.beta.-methyl-
4-(phenylmethyl)- (Ifenprodil);
ACEA 1168; and
30 (1S,2S)-1-(4-Hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidine)-
1-propanol.

-104-

20. The combination of Claim 1 wherein the analgesic is an NK₁ receptor antagonist.
21. The combination of Claim 1 wherein the analgesic is an NK₁ receptor antagonist named:
- 5 [2-(1*H*-indol-3-yl)-1-methyl-1-(1-phenyl-ethylcarbamoyl)-ethyl]-
 carbamic acid benzofuran-2-ylmethyl ester.
22. The combination of Claim 1 wherein the analgesic is an opioid.
23. The combination of Claim 1 wherein the analgesic is an opioid selected from:
- 10 Codeine;
 Morphine;
 Hydromorphone;
 Levorphanol;
 Methadone;
15 Oxycodone;
 Hydrocodone;
 Pentazocine;
 Nalbuphine;
 Butorphanol;
20 Hydromorphone; and
 Naloxone.
24. The combination of Claim 1 wherein the endothelin receptor antagonist is 2R-(4-methoxyphenyl)-4S-(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)-aminocarbonyl-methyl)-pyrrolidine-3R-carboxylic acid (ABT-627).
- 25 25. A combination of Claim 1 comprising a pain alleviating effective amount of an endothelin antagonist or a pharmaceutically acceptable salt thereof and one or two antiepileptics compounds having pain alleviating properties, and pharmaceutically acceptable salts thereof.

-105-

26. The combination of Claim 1 wherein the endothelin receptor antagonist is selected from:

4-(3,5-Dimethyl-phenyl)-1,1-dioxo-2-(2-trifluoromethyl-phenyl)-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid,

5 4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2*H*-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide, and

4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2*H*-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide, potassium salt; and

10 the antiepileptic compound having pain alleviating properties is selected from gabapentin, pregabalin, and 3-(1-aminomethyl-cyclohexylmethyl)-4*H*-[1,2,4]oxadiazol-5-one hydrochloride.

27. The combination of Claim 1 wherein the endothelin receptor antagonist is 4-(7-ethyl-1,3-benzodioxol-5-yl)-2-[2-trifluoromethyl)phenyl]-2*H*-1,2-
- 15 dihydro-1,2-benzothiazine-3-carboxylic acid 1,1-dioxide potassium salt and the antiepileptic compound having pain alleviating properties is gabapentin.

28. The combination of Claim 1 wherein the endothelin receptor antagonist is 4-(7-ethyl-1,3-benzodioxol-5-yl)-2-[2-trifluoromethyl)phenyl]-2*H*-1,2-

20 dihydro-1,2-benzothiazine-3-carboxylic acid 1,1-dioxide potassium salt and the antiepileptic compound having pain alleviating properties is pregabalin.

29. The combination of Claim 1 wherein the endothelin receptor antagonist is 4-(7-ethyl-1,3-benzodioxol-5-yl)-2-[2-trifluoromethyl)phenyl]-2*H*-1,2-

25 dihydro-1,2-benzothiazine-3-carboxylic acid 1,1-dioxide potassium salt and the antiepileptic compound having pain alleviating properties is 3-(1-aminomethyl-cyclohexylmethyl)-4*H*-[1,2,4]oxadiazol-5-one hydrochloride.

-106-

30. A combination of Claim 1 comprising a pain alleviating effective amount of an endothelin antagonist or a pharmaceutically acceptable salt thereof and one or two analgesics, and pharmaceutically acceptable salts thereof.
- 5 31. A combination of Claim 1 comprising a pain alleviating effective amount of an endothelin antagonist or a pharmaceutically acceptable salt thereof and one or two analgesics, and pharmaceutically acceptable salts thereof wherein the analgesic is an opioid analgesic.
32. The combination of Claim 1 wherein the endothelin receptor antagonist is selected from:
- 10 4-(3,5-Dimethyl-phenyl)-1,1-dioxo-2-(2-trifluoromethyl-phenyl)-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid;
4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2H-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide; and
4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-
15 2H-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide, potassium salt; and
the analgesic is an opioid analgesic selected from:
- Codeine;
Morphine;
20 Hydromorphone;
Levorphanol;
Methadone;
Oxycodone;
Hydrocodone;
25 Pentazocine;
Nalbuphine;
Butorphanol;
Hydromorphone; and
Naloxone.

-107-

33. A combination of Claim 1 comprising a pain alleviating effective amount of an endothelin antagonist or a pharmaceutically acceptable salt thereof and one or two analgesics, and pharmaceutically acceptable salts thereof wherein the analgesic is a nonopioid analgesic.

5 34. The combination of Claim 1 wherein the analgesic is an NSAID nonopioid analgesic.

35. The combination of Claim 1 wherein the endothelin receptor antagonist is selected from:

10 4-(3,5-Dimethyl-phenyl)-1,1-dioxo-2-(2-trifluoromethyl-phenyl)-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid;

4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2*H*-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide; and

15 4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2*H*-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide, potassium salt; and

the analgesic is an NSAID nonopioid analgesic selected from:

Naproxen;

Naproxen sodium;

Ibuprofen;

20 Acetaminophen;

Aspirin;

Sulindac;

Tolmetin;

Piroxicam;

25 Mefenamic acid;

Phenylbutazone;

Fenoprofen;

Ketoprofen;

Suprofen;

30 Diflunisal;

Celecoxib;

-108-

Meloxicam; and

(Z)-5-[[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]-
methylene]-2-imino-4-thiazolidinone methanesulfonate (1:1).

36. The combination of Claim 1 wherein the analgesic is an NMDA receptor
antagonist nonopioid analgesic.

37. The combination of Claim 1 wherein the endothelin receptor antagonist is
selected from:

4-(3,5-Dimethyl-phenyl)-1,1-dioxo-2-(2-trifluoromethyl-phenyl)-
1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid;

4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-
2*H*-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide; and

4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-
2*H*-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide,
potassium salt; and

the analgesic is a nonopioid analgesic selected from:

1*H*-Indole-2-carboxylic acid, 4,6-dichloro-3-[3-oxo-
3-(phenylamino)-1-propenyl]-, (E)- (GV-150526);

1-Piperidineethanol, .alpha.-(4-hydroxyphenyl)-.beta.-methyl-
4-(phenylmethyl)- (Ifenprodil);

ACEA 1168; and

(1*S*,2*S*)-1-(4-Hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidine)-
1-propanol.

38. The combination of Claim 1 wherein the endothelin receptor antagonist is
selected from:

4-(3,5-Dimethyl-phenyl)-1,1-dioxo-2-(2-trifluoromethyl-phenyl)-
1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid;

4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-
2*H*-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide; and

-109-

4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-
2H-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide,
potassium salt;

and the analgesic is a nonopioid analgesic named:

[2-(1*H*-Indol-3-yl)-1-methyl-1-(1-phenyl-ethylcarbamoyl)-ethyl]-
carbamic acid benzofuran-2-ylmethyl ester.

39. A combination of Claim 1 comprising a pain alleviating effective amount
of an endothelin antagonist or a pharmaceutically acceptable salt thereof
and one antiepileptic compound having pain alleviating properties and one
analgesic.

40. A combination of Claim 1 comprising a pain alleviating effective amount
of an endothelin antagonist or a pharmaceutically acceptable salt thereof
and one antiepileptic compound having pain alleviating properties and one
analgesic wherein the analgesic is an opioid analgesic.

41. The combination of Claim 1 wherein the endothelin receptor antagonist is
selected from:

4-(3,5-Dimethyl-phenyl)-1,1-dioxo-2-(2-trifluoromethyl-phenyl)-
1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid;

4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-
2H-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide; and

4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-
2H-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide,
potassium salt;

the antiepileptic is selected from gabapentin, pregabalin, and 3-(1-
aminomethyl-cyclohexylmethyl)-4H-[1,2,4]oxadiazol-5-one
hydrochloride; and

the analgesic is an opioid analgesic selected from:

Codeine;

Morphine;

Hydromorphone;

-110-

Levorphanol;
Methadone;
Oxycodone;
Hydrocodone;
5 Pentazocine;
Nalbuphine;
Butorphanol;
Hydromorphone; and
Naloxone.

10 42. A combination of Claim 1 comprising a pain alleviating effective amount
of an endothelin receptor antagonist or a pharmaceutically acceptable salt
thereof and one antiepileptic compound having pain alleviating properties
and one analgesic wherein the analgesic is a nonopioid analgesic.

15 43. The combination of Claim 1 wherein the endothelin receptor antagonist is
selected from:

4-(3,5-Dimethyl-phenyl)-1,1-dioxo-2-(2-trifluoromethyl-phenyl)-
1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid;

4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-
2H-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide; and

20 4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-
2H-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide,
potassium salt;

the antiepileptic compound having pain alleviating properties is
selected from gabapentin, pregabalin, and 3-(1-aminomethyl-
25 cyclohexylmethyl)-4H-[1,2,4]oxadiazol-5-one hydrochloride; and

the analgesic is a nonopioid analgesic selected from:

Naproxen;

Naproxen sodium;

Ibuprofen;

30 Acetaminophen;

Aspirin;

-111-

Sulindac;

Tolmetin;

Piroxicam;

Mefenamic acid;

5 Phenylbutazone;

Fenoprofen;

Ketoprofen;

Suprofen;

Diflunisal;

10 Celecoxib;

Meloxicam;

(Z)-5-[[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]-
methylene]-2-imino-4-thiazolidinone methanesulfonate (1:1);

15 [2-(1*H*-Indol-3-yl)-1-methyl-1-(1-phenyl-ethylcarbamoyl)-
ethyl]-carbamic acid benzofuran-2-ylmethyl ester;

1*H*-Indole-2-carboxylic acid, 4,6-dichloro-3-[3-oxo-
3-(phenylamino)-1-propenyl]-, (E)- (GV-150526);

1-Piperidineethanol, .alpha.-(4-hydroxyphenyl)-.beta.-
methyl-4-(phenylmethyl)- (Ifenprodil);

20 ACEA 1168; and

(1*S*,2*S*)-1-(4-Hydroxyphenyl)-2-(4-hydroxy-
4-phenylpiperidine)-1-propanol.

44. A combination of Claim 1 comprising a pain alleviating effective amount
of an endothelin antagonist or a pharmaceutically acceptable salt thereof
25 and two analgesics wherein one analgesic is an opioid analgesic and one
analgesic is a nonopioid analgesic.

45. The combination of Claim 1 wherein the endothelin receptor antagonist is
selected from:

4-(3,5-Dimethyl-phenyl)-1,1-dioxo-2-(2-trifluoromethyl-phenyl)-
1,2-dihydro-1*H*-benzo[e][1,2]thiazine-3-carboxylic acid;

30

-112-

4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-
2*H*-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide; and

4-(7-Ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-
2*H*-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide,
5 potassium salt;

the one analgesic is an opioid analgesic selected from:

Codeine;

Morphine;

Hydromorphone;

10 Levorphanol;

Methadone;

Oxycodone;

Hydrocodone;

Pentazocine;

15 Nalbuphine;

Butorphanol;

Hydromorphone; and

Naloxone; and

one analgesic is a nonopioid analgesic selected from:

20 Naproxen;

Naproxen sodium;

Ibuprofen;

Acetaminophen;

Aspirin;

25 Sulindac;

Tolmetin;

Piroxicam;

Mefenamic acid;

Phenylbutazone;

30 Fenoprofen;

Ketoprofen;

Suprofen;

Diffunisal;

-113-

Celecoxib;

Meloxicam;

(Z)-5-[[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]-
methylene]-2-imino-4-thiazolidinone methanesulfonate (1:1);

5 [2-(1*H*-Indol-3-yl)-1-methyl-1-(1-phenyl-ethylcarbamoyl)-
ethyl]-carbamic acid benzofuran-2-ylmethyl ester;

1*H*-Indole-2-carboxylic acid, 4,6-dichloro-3-[3-oxo-
3-(phenylamino)-1-propenyl]-, (E)- (GV-150526);

10 1-Piperidineethanol, .alpha.-(4-hydroxyphenyl)-.beta.-
methyl-4-(phenylmethyl)- (Ifenprodil);

ACEA 1168; and

(1*S*,2*S*)-1-(4-Hydroxyphenyl)-2-(4-hydroxy-
4-phenylpiperidine)-1-propanol.

- 15 46. A method of treating pain in a mammal suffering therefrom, comprising
administering a pain alleviating effective amount of a combination of
Claim 1.
- 20 47. A method according to Claim 46 wherein the pain being treated is selected
from the group consisting of: centrally mediated pain, peripherally
mediated pain, structural pain, soft tissue pain, injury-related pain,
progressive disease-related pain, and neuropathic pain.
48. The method according to Claim 46 wherein the pain being treated is
diabetic peripheral neuropathy.
- 25 49. The method according to Claim 46 wherein the combination administered
comprises an endothelin receptor antagonist which is 4-(7-ethyl-1,3-
benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2*H*-1,2-dihydro-1,2-
benzothiazine-3-carboxylic acid, 1,1-dioxide, potassium salt, and an
antiepileptic compound having pain alleviating properties which is
gabapentin.

-114-

50. The method according to Claim 46 wherein the combination administered comprises an endothelin receptor antagonist which is 4-(7-ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2H-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide, potassium salt, and an antiepileptic compound having pain alleviating properties which is pregabalin.
51. The method according to Claim 46 wherein the combination administered comprises an endothelin receptor antagonist which is 4-(7-ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2H-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide, potassium salt, and an antiepileptic compound having pain alleviating properties which is 3-(1-aminomethyl-cyclohexylmethyl)-4H-[1,2,4]oxadiazol-5-one hydrochloride.
52. The method according to Claim 46 wherein the pain being treated is diabetic peripheral neuropathy and the combination administered comprises an endothelin receptor antagonist which is 4-(7-ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2H-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide, potassium salt, and an antiepileptic compound having pain alleviating properties which is gabapentin.
53. The method according to Claim 46 wherein the pain being treated is diabetic peripheral neuropathy and the combination administered comprises an endothelin receptor antagonist which is 4-(7-ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2H-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide, potassium salt, and an antiepileptic compound having pain alleviating properties which is pregabalin.
54. The method according to Claim 46 wherein the pain being treated is diabetic peripheral neuropathy and the combination administered

-115-

comprises an endothelin receptor antagonist which is 4-(7-ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2H-1,2-dihydro-1,2-benzothiazine-3-carboxylic acid, 1,1-dioxide, potassium salt, and an antiepileptic compound having pain alleviating properties which is 3-(1-aminomethyl-cyclohexylmethyl)-4H-[1,2,4]oxadiazol-5-one hydrochloride.

55. The method according to Claim 46 wherein the combination administered comprises an endothelin receptor antagonist which is 4-(3,5-dimethyl-phenyl)-1,1-dioxide-2-(2-trifluoromethyl-phenyl)-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid, and an antiepileptic compound having pain alleviating properties which is gabapentin.


56. The method according to Claim 46 wherein the combination administered comprises an endothelin receptor antagonist which is 4-(3,5-dimethyl-phenyl)-1,1-dioxide-2-(2-trifluoromethyl-phenyl)-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid, and an antiepileptic compound having pain alleviating properties which is pregabalin.

57. The method according to Claim 46 wherein the combination administered comprises an endothelin receptor antagonist which is 4-(3,5-dimethyl-phenyl)-1,1-dioxide-2-(2-trifluoromethyl-phenyl)-1,2-dihydro-1 λ ⁶-benzo[e][1,2]thiazine-3-carboxylic acid, and an antiepileptic compound having pain alleviating properties which is 3-(1-aminomethyl-cyclohexylmethyl)-4H-[1,2,4]oxadiazol-5-one hydrochloride.

58. A pharmaceutical composition comprising a pain alleviating effective amount of a combination of Claim 1, and a pharmaceutically acceptable excipient, diluent, or carrier.


59. A method of treating pain in a mammal suffering therefrom, comprising administering a pain alleviating effective amount of a pharmaceutical composition of Claim 58.

1/4




2/4

FIG. 2 1:1 GABAPENTIN:COMPOUND (1)




3/4

FIG. 3 3:1 GABAPENTIN:COMPOUND (1)



4/4



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 December 2001 (06.12.2001)

PCT

(10) International Publication Number
WO 01/091736 A3

(51) International Patent Classification⁷: A61K 45/06,
A61P 29/00

(21) International Application Number: PCT/US01/14793

(22) International Filing Date: 8 May 2001 (08.05.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/208,259 31 May 2000 (31.05.2000) US

(71) Applicant (*for all designated States except US*):
WARNER-LAMBERT COMPANY [—/US]; 201
Tabor Road, Morris Plains, NJ 07950 (US).

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): DOOLEY, David,
James [US/US]; 10614 Swallowtail Court, South Lyon,
MI 48178 (US).

(74) Agents: FEDERMAN, Evan, J.; Warner-Lambert Com-
pany, 201 Tabor Road, Morris Plains, NJ 07950 et al. (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
17 October 2002

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: COMBINATIONS OF AN ENDOTHELIN RECEPTOR ANTAGONIST AND AN ANTIEPILEPTIC COMPOUND
HAVING PAIN ALLEVIATING PROPERTIES OR ANALGESIC

(57) Abstract: The present invention is a novel combination effective for alleviating pain comprising a pain alleviating effective amount of an endothelin receptor antagonist or a pharmaceutically acceptable salt thereof and from 1 to 3 compounds independently selected from the group consisting of antiepileptic compounds having pain alleviating properties and analgesics, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising same. The administration of endothelin receptor antagonists in these novel combinations results in an improved reduction in the frequency and severity of pain. The incidence of unwanted side effects can be reduced by these novel combinations in comparison to using higher doses of a single agent treatment to achieve a similar therapeutic effect. The present invention is also directed to methods of using effective amounts of the novel combinations and pharmaceutical compositions thereof to treat pain in mammals, including a human.

WO 01/091736 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/14793

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 A61K45/06 A61P29/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, WPI Data, BIOSIS, CHEM ABS Data, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Description of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 09818 A (MERCK) 4 April 1996 (1996-04-04) claims 1-3 page 4, line 21-30	1, 9, 22, 30, 31, 46, 58, 59
A	WO 99 12916 A (WARNER-LAMBERT) 18 March 1999 (1999-03-18) cited in the application claims 1, 5, 7 page 2, line 1-5 --- -/-	1, 9, 11-13, 22, 30, 31, 46, 58, 59

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

27 June 2002

Date of mailing of the international search report

03/07/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Peeters, J

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/14793

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96 26195 A (WARNER-LAMBERT) 29 August 1996 (1996-08-29) claims 1-4 page 16, line 1-8 -----	1,9,11, 22,30, 31,46, 58,59

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 01/14793

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: —
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☒ Claims Nos.: —
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 46-57,59 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.1

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

Continuation of Box I.2

Present claims 1-5,9-11,16,17,19,23,26,32,35,37,38,41,43,45 relate to an extremely large number of possible compounds/products/methods. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds/products/methods claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those compounds/products/methods described in the examples with due regard to the general idea underlying the present application.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/14793

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9609818	A	04-04-1996	AU 3642795 A WO 9609818 A1	19-04-1996 04-04-1996
WO 9912916	A	18-03-1999	AU 9019698 A BR 9812431 A EP 1009743 A1 HU 0003689 A2 JP 2001515893 T NO 20001078 A PL 338983 A1 WO 9912916 A1 US 6265399 B1 US 6252070 B1 US 2001036944 A1 ZA 9808122 A	29-03-1999 19-09-2000 21-06-2000 28-09-2001 25-09-2001 02-03-2000 04-12-2000 18-03-1999 24-07-2001 26-06-2001 01-11-2001 05-03-1999
WO 9626195	A	29-08-1996	US 5599811 A AT 207911 T AU 720036 B2 AU 4770396 A BG 62613 B1 BG 101867 A CA 2211027 A1 CN 1180351 A ,B CZ 9702607 A3 DE 69616515 D1 DE 69616515 T2 DK 811001 T3 EE 9700147 A EP 0811001 A1 ES 2167544 T3 FI 973380 A HU 9800273 A2 JP 11501013 T NO 973822 A NZ 302116 A PL 321866 A1 RO 116898 B RU 2164225 C2 SI 811001 T1 SK 114697 A3 WO 9626195 A1 ZA 9601342 A	04-02-1997 15-11-2001 18-05-2000 11-09-1996 31-03-2000 30-10-1998 29-08-1996 29-04-1998 17-06-1998 06-12-2001 16-05-2002 18-02-2002 15-12-1997 10-12-1997 16-05-2002 20-08-1997 28-07-1999 26-01-1999 21-08-1997 26-06-1998 22-12-1997 30-07-2001 20-03-2001 30-04-2002 05-08-1998 29-08-1996 26-08-1996